Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 17290. Отображено 100.
12-01-2012 дата публикации

Acid-free quaternized nitrogen compounds and use thereof as additives in fuels and lubricants

Номер: US20120010112A1
Принадлежит: BASF SE

The present invention relates to novel acid-free quaternized nitrogen compounds, to the preparation thereof and to the use thereof as a fuel and lubricant additive, more particularly as a detergent additive, as a wax antisettling additive (WASA) or as an additive for reducing internal diesel injector deposits (IDID); to additive packages which comprise these compounds; and to fuels and lubricants thus additized. The present invention further relates to the use of these acid-free quaternized nitrogen compounds as a fuel additive for reducing or preventing deposits in the injection systems of direct-injection diesel engines, especially in common-rail injection systems, for reducing the fuel consumption of direct-injection diesel engines, especially of diesel engines with common-rail injection systems, and for minimizing power loss in direct-injection diesel engines, especially in diesel engines with common-rail injection systems.

Подробнее
23-02-2012 дата публикации

Intermediates in the enantioselective synthesis of 3-(aminomethyl)-5-methyl-hexanoic acid

Номер: US20120046468A1

(S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid or (S)-pregabalin is an anticonvulsive drug. In addition to its use as an anticonvulsive agent, pregabalin has also been indicated as a medicament in the treatment of anxiety, neuropathic pain and pain in patients with fibromyalgia. Provided herein are thioester intermediates in the synthesis of and processes for the synthesis of 3-(aminomethyl)-5-methyl-hexanoic acid in the (R) or (S) configuration.

Подробнее
15-03-2012 дата публикации

Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8-aminocaprylic acid

Номер: US20120065128A1
Принадлежит: Emisphere Technologies Inc

The present invention relates to crystalline polymorphic forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, pharmaceutical compositions containing the same, methods of preparing the same, and methods for facilitating the delivery of active agents with the same.

Подробнее
29-03-2012 дата публикации

Process for the preparation of cilastatin and sodium salt

Номер: US20120078009A1

An improved process for preparing Cilastatin Sodium including dissolving Cilastatin acid in a solvent using an organic base, adding sodium salt of a week acid and isolating Cilastatin Sodium.

Подробнее
12-04-2012 дата публикации

Process for the preparation of a iodinating agen

Номер: US20120088926A1
Принадлежит: BRACCO IMAGING SPA

The present invention describes a process for the synthesis of a iodinating agent, being said iodinating agent iodine chloride (ICI.) In particular, the present invention relates to a process for the electrochemical preparation of ICI, as a useful iodinating agent in the preparation of iodinated organic compounds for use as contrast agents or their precursors in the synthesis of the same.

Подробнее
24-05-2012 дата публикации

Method of preparing 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane

Номер: US20120130127A1
Принадлежит: Mer Pharma GmbH and Co KGaA

Method of preparing 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane, an intermediate in the synthesis of 1-amino-1,3,3,5,5-pentamethylcyclohexane (Neramexane) or a pharmaceutically acceptable salt thereof, comprising step (iii): (iii) reacting 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane with chloroacetonitrile in the presence of an acid, wherein 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane is employed in step (iii) as obtained in the reaction of a methylmagnesium halide with 3,3,5,5-tetramethylcyclohexanone without having been subjected to a purification step.

Подробнее
28-06-2012 дата публикации

Novel compound and method for preparing the same

Номер: US20120165572A1
Принадлежит: Fujifilm Corp

The invention is directed to a compound represented by the Formula (1) as defined herein, and a method for preparing a compound represented by the Formula (1) which includes: reacting a diamine compound represented by the Formula (2) as defined herein with a methacrylic anhydride or an acrylic anhydride under a condition where an organic acid having a pKa of 2.0 or more is present in an amount of 0.5 to 5.0 moles based on 1 mole of the diamine compound to obtain a reaction mixture; adding phosphoric acid to the reaction mixture; and purifying the reaction mixture by extraction with an organic solvent.

Подробнее
05-07-2012 дата публикации

Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives

Номер: US20120172426A1
Принадлежит: Reviva Pharmaceuticals Inc

The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.

Подробнее
19-07-2012 дата публикации

Reduction of fused bicyclic impurities in triiodinated x-ray contrast media

Номер: US20120184773A1
Принадлежит: Mallinckrodt LLC

The present disclosure generally relates to an improved process for alkylating a triiodo-substituted arylamide to form a compound suitable for use as an X-ray contrast agent. More particularly, the present disclosure is directed to such a process that limits the formation of fused bicyclic impurities, such as Impurity G, in the alkylation reaction mixture.

Подробнее
26-07-2012 дата публикации

Hydrochlorination of electron-deficient alkenes

Номер: US20120190879A1
Автор: Michael Todd Coleman
Принадлежит: Future Fuel Chemical Co

The present invention pertains to a method for the hydrochlorination of electron deficient alkenes, particularly alkenes having the functional groups COOH, CONH 2 , and CN. Specific alkenes discussed include acrylic acid, crotonic acid, methacrylic acid, acrylonitrile, acrylamide, and methacrylonitrile. The alkene is combined with a primary or secondary alcohol (e.g., isopropanol) and an acid chloride (e.g., acetyl chloride) under conditions suitable to chlorinate the alkene. Products formed by the invention include 3-chorosubstituted carbonyl compounds such as 3-chlorpropionic acid (3-CPA), 3-chloropropionamide (3-CPAD), and 3-chloropropionitrile among other products.

Подробнее
23-08-2012 дата публикации

Viral polymerase inhibitors

Номер: US20120214783A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds of formula I: wherein X, R 2 , R 3 , R 3a , R 3b , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

Подробнее
06-09-2012 дата публикации

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease

Номер: US20120225890A1
Принадлежит: ProteoTech Inc

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
08-11-2012 дата публикации

Intermediate compounds and processes for the preparation of tapentadol and related compounds

Номер: US20120283463A1
Принадлежит: Mapi Pharma Ltd

The present invention discloses processes for the preparation of 3-[(1R,2R)-3-(dimethyl-amino)-1-ethyl-2-methyl-propyl]phenol (Tapentadol), salts thereof and related compounds of formula (A), including stereoisomers and pharmaceutically acceptable salts thereof, and to certain intermediates used in such process.

Подробнее
15-11-2012 дата публикации

Perfluoropolyether-containing compounds with oxalylamino groups

Номер: US20120289736A1
Принадлежит: 3M Innovative Properties Co

Compounds containing at least one perfluoropolyether segment and at least two oxalylamino groups as well as methods of making these compounds are described. The compounds can be polymeric materials or can be used in the preparation of various copolymeric materials by reaction with compounds having at least two primary or secondary amino groups.

Подробнее
27-12-2012 дата публикации

Taste Improving Substances

Номер: US20120328536A1
Принадлежит: Quest International Services BV

The present invention relates to taste improvement of foodstuffs, beverages, tobacco products and oral care products, using a substance according to formula (I), edible salts or edible esters thereof: It was found that substances represented by formula (I) are capable of modifying and complementing, the sensory impact of taste imparting substances. Thus, the present taste improving substances are advantageously applied in flavour compositions, foodstuffs, tobacco products and oral care products. Typical examples of taste improving substances according to the present invention include N-(2-hydroxyethyl) 3-hydroxypropionamide; N-(2-hydroxyethyl) 3-hydroxybutyramide; N-(2-hydroxyethyl) 4-hydroxybutyramide; N-(2-hydroxyethyl) N-5-hydroxypentanoylamide; N-(2-hydroxyethyl) 4-hydroxypentanoylamide; N-(2-hydroxyethyl) 3-hydroxypentanoylamide; N-(2-hydroxyethyl) 2-methyl-4-hydroxy-butyramide; N-(2-hydroxyethyl) 2-methyl-3-hydroxybutyramide; N-(2-hydroxyethyl) N-6-hydroxyhexanoylamide; N-(2-hydroxyethyl) 5-hydroxyhexanoylamide; N-(2-hydroxyethyl) 4-hydroxyhexanoylamide; N-(2-hydroxyethyl) 3-hydroxyhexanoylamide; N-(2-hydroxyethyl) 4-hydroxy-2-keto-3-methyl-pentanoylamide; N-(2-hydroxyethyl) 4-hydroxy-2-keto-3-methyl-hexanoylamide and mixtures thereof.

Подробнее
27-12-2012 дата публикации

Bis-phosphate compound and asymmetric reaction using the same

Номер: US20120330038A1
Принадлежит: API Corp, Tohoku University NUC

A novel bis-phosphate compound is provided which can be applied to a wide range of reactive substrates and reactions as an asymmetric reaction catalyst and can realize an asymmetric reaction affording a high yield and a high enantiomeric excess. The bis-phosphate compound has a tetraaryl skeleton represented by General Formula (1). In an asymmetric reaction, an amidodiene and an unsaturated aldehyde compound are reacted with each other in the presence of the optically active bis-phosphate compound to give an optically active amidoaldehyde. The invention allows a reaction such as an asymmetric Diels-Alder reaction to proceed efficiently, which has been difficult with conventional mono-phosphate compounds. Thus, the invention enables an industrially feasible method for the production of optically active amidoaldehydes, optically active β-amino acid derivatives, optically active diamine compounds, optically active pyrrolidine derivatives and optically active dihydropyran derivatives which are useful as products such as medicines, agricultural chemicals and chemical products as well as synthesis intermediates for such products.

Подробнее
03-01-2013 дата публикации

Agomelatine hydrochloride hydrate and preparation thereof

Номер: US20130005820A1
Принадлежит: Laboratoires Servier SAS

The present invention relates to an agomelatine hydrochloride hydrate of formula I, preparation and use thereof, and to pharmaceutical composition containing it. The agomelatine hydrohalide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps. wherein X is Cl.

Подробнее
31-01-2013 дата публикации

Process for the preparation of lacosamide

Номер: US20130030216A1
Принадлежит: EUTICALS SPA

A novel process for the synthesis of Lacosamide using D,L-serine as starting material is described, where the methylation reaction of hydroxyl is carried out using an inexpensive base such as NaOH and an inexpensive alkylating agent, non-toxic and non-carcinogenic, such as methyl p-toluenesulfonate; the R enantiomer is isolated from the racemic mixture of Lacosamide after selective hydrolysis of the acetamide, salification of the racemic mixture with a chiral acid (HX*) in an organic solvent, resolution of the diastereoisomeric mixture, preferably by precipitation of the R enantiomer, and subsequent acetylation of the optically pure intermediate.

Подробнее
14-02-2013 дата публикации

Chemoselective enrichment for compound isolation

Номер: US20130041106A1

Chemoselective isolation of hydroxyl group-containing and carboxyl group-containing compounds is accomplished via formation of polymeric silyl ethers and polymeric siloxyl esters, respectively. Preparation of chemoselective polymeric reagents for capture of hydroxyl group containing compounds and carboxyl group containing compounds is described.

Подробнее
21-02-2013 дата публикации

Method for the Hydrolysis of Substituted Formylamines into Substituted Amines

Номер: US20130046111A1
Автор: Mikhail Bobylev
Принадлежит: Individual

An improved method for the synthesis of substituted formylamines and substituted amines via an accelerated Leuckart reaction. The Leuckart reaction is accelerated by reacting formamide or N-alkylformamide and formic acid with an aldehyde or a ketone at a preferred molar ratio that accelerates the reaction. The improved method is applicable to various substituted aldehydes and ketones, including substituted benzaldehydes. An accelerated method for the hydrolysis of substituted formylamines into substituted amines using acid or base and a solvent at an elevated temperature. The improved method is useful for the accelerated synthesis of agrochemicals and pharmaceuticals such as vanillylamine, amphetamine and its analogs, and formamide fungicides.

Подробнее
21-03-2013 дата публикации

Process for Producing Aliskiren

Номер: US20130071899A1
Принадлежит: Chemo Iberica SA

A new route of synthesis of the compound Aliskiren of formula (I), used in the treatment of hypertension, is described.

Подробнее
21-03-2013 дата публикации

18ß-GLYCYRRHETINIC ACID DERIVATIVES AND SYNTHETIC METHOD THEREOF

Номер: US20130072694A1
Принадлежит: KAOHSIUNG MEDICAL UNIVERSITY

The present invention provides a chemical compound having the structure being one selected from a group consisting of 2. The method according to further comprising a step of using an isopropylamine solution as the amine solution when Ris CONHCH(CH) claim 1 , and using an aniline solution as the amine solution when Ris CONHCH.3. The method according to further comprising steps of:methylating the 18β-glycyrrhetinic acid to obtain a methylated 18β-glycyrrhetinic acid; andoxidizing the methylated 18β-glycyrrhetinic acid to obtain a second compound.4. The method according to further comprising a step of esterifying the lactone compound to obtain a first derivative of the lactone compound.5. The method according to further comprising a step of cleaving a lactone ring of the lactone compound to obtain a second derivative of the lactone compound.6. The method according to further comprising a step of treating the second derivative with an alcohol solution to obtain a third derivative of the lactone compound.7. The method according to claim 6 , wherein the alcohol solution is one of an isopropyl alcohol solution and a benzyl alcohol solution.8. The method according to further comprising a step of esterifying the second compound with an alcohol solution to obtain a fourth derivative of the lactone compound.9. The method according to further comprising a step of cleaving a lactone ring of the fourth derivative by an acidic solution to obtain a fifth derivative of the lactone compound.13. The method according to claim 12 , wherein the chemical compound with Rbeing one of CONHCH(CH)and CONHCHis obtained by steps of:oxidizing the 18β-glycyrrhetinic acid to form a first compound;treating the first compound with an m-chloroperbenzoic acid to afford a lactone compound; andtreating the lactone compound with an amine solution to obtain the chemical compound being a first derivative of the chemical compound.14. The method according to further comprising a step of using an ...

Подробнее
21-03-2013 дата публикации

ENANTIOMERICALLY PURE AMINES

Номер: US20130072711A1
Принадлежит: NABRIVA THERAPEUTICS AG

A compound of formula 3. A compound according to claim 1 , wherein PROT and PROT′ together with the nitrogen atom to which are attached form phthalimido-N-yl.4. A compound according to claim 1 ,wherein PROT″ is benzoyl or trityl.7. A compound according to claim 1 , selected from the group consisting of:{(1R,2R,4R)-4-[(tert-Butoxycarbonyl)-amino]-2-hydroxy-cyclohexyl}-benzene-carbothioate,{(1R,2R,4R)-4-[(2,2,2-Trifluoro-acetyl)-amino]-2-hydroxy-cyclohexyl}-benzene-carbothioate,tert-Butyl [(1R,3R,4R)-3-hydroxy-4-tritylsulfanyl-cyclohexyl]-carbamate, and2,2,2-Trifluoro-N-((1R,3R,4R)-3-hydroxy-4-tritylsulfanyl-cyclohexyl)-acetamide.10. A compound of formula II claim 9 , II claim 9 , IIor IIaccording to claim 9 , selected from the group consisting oftert-Butyl (1R,3R,6R)-(7-oxa-bicyclo[4.1.0]hept-3-yl)-carbamate, and2,2,2-Trifluoro-N-(1R,3R,6S)-(7-oxa-bicyclo[4.1.0]hept-3-yl)-acetamide.12. A process according to claim 11 , wherein none of the intermediates obtained in a) to d) is isolated.13. A process according to claim 11 , wherein the reaction a) to e) is performed in a single solvent (system).14. (canceled) The present invention relates to enantiomerically pure amines, such as amino and thio protected hydroxy-mercapto-cyclohexyl amines and production processes thereof.Organic compounds, such as cyclohexyl amines containing an asymmetric carbon atom may exist in the form of enantiomers, diastereoisomers and mixtures thereof, e.g. racemates. Such compounds may exist in the (R)-, (S)- or (R,S)-configuration. For pharmaceutical use it is often vital to have an active compound comprising an asymmetric carbon atom in one of the enantiomerically pure forms, since one isomer may differ, e.g. in several aspects from another isomer, e.g. one isomer may be more active than the other isomer. Separation of isomers is often burdensome. Chromatography which, for example, may be useful for isomeric separation, is on technical scale not easy to carry out and often needs sophisticated ...

Подробнее
21-03-2013 дата публикации

Process For The Iodination Of Phenolic Derivatives

Номер: US20130072719A1
Принадлежит: BRACCO IMAGING S.P.A.

The present invention relates to a process for the preparation of iodinated phenols; in particular; it relates to a process including the direct iodination, with suitably activated iodine, of 3,5-disubstituted phenol compounds to the corresponding 3,5-disubstituted-2,4,6-triiodophenols, which are useful intermediates for the synthesis of x-ray contrast media, and to the preparation of the contrast media themselves. 2. The process of wherein claim 1 , within the compounds of formulae 1 and 2 claim 1 , R and R′ represent claim 1 , independently claim 1 , a group of formula —NHRor —NRRwherein each R claim 1 , Rand Ris claim 1 , independently claim 1 , a straight or branched C-Calkyl group optionally substituted by one to three hydroxyl groups.3. The process of wherein claim 2 , within the compounds of formulae 1 and 2 claim 2 , R and R′ represent claim 2 , independently claim 2 , a group selected from:{'sub': '3', '—NHCH,'}{'sub': 2', '2, '—NHCH—CH(OH)—CHOH,'}{'sub': 2', '2, '—NHCH(CHOH), and'}{'sub': 3', '2', '2, '—N(CH)—CH—CH(OH)—CHOH.'}4. The process of wherein the molar ratio between molecular iodine and 3 claim 1 ,5-disubstituted phenol substrate 1 [I/1] is comprised from 1.1 to 1.3 claim 1 , and the molar ratio between iodic acid and 3 claim 1 ,5-disubstituted phenol substrate 1 is comprised from 0.4 to 0.8.5. The process according to wherein the triiodination of the 3 claim 4 ,5-disubstituted phenol substrate 1 with iodine and iodic acid is carried out by using a molar ratio 3 claim 4 ,5-disubstituted phenol substrate:iodine:iodic acid of 1:1.2:0.6.6. The process according to wherein said aqueous medium is water or an aqueous solution.7. The process of comprising: obtaining an aqueous solution of 3 claim 6 ,5-di-substituted phenol substrate of formula 1 claim 6 , or of a salt thereof claim 6 , and adding Iand HIOto said aqueous solution.8. The process according to wherein said aqueous solution of 3 claim 7 ,5-di-substituted phenol substrate is a crude solution ...

Подробнее
28-03-2013 дата публикации

Process for preparing eddn and edmn

Номер: US20130079492A1
Принадлежит: BASF SE

A process for preparing EDDN and/or EDMN by conversion of FA, HCN and EDA, the reaction being effected in the presence of water, and, after the conversion, water being depleted from the reaction mixture in a distillation column, which comprises performing the distillation in the presence of an organic solvent which has a boiling point between water and EDDN and/or EDMN at the distillation pressure existing in the column or which forms a low-boiling azeotrope with water.

Подробнее
28-03-2013 дата публикации

METHOD FOR PREPARING ALKYL LACTATE AND A METHOD FOR PREPARING LACTAMIDE USING THE SAME

Номер: US20130079547A1
Принадлежит: LG CHEM, LTD.

This disclosure relates to a method for preparing alkyl lactate with high yield and high selectivity, comprising the step of reacting glycerol with water or alcohol in the presence of a catalyst. 2. The method according to claim 1 , wherein the catalyst is a homogeneous or heterogeneous catalyst.3. The method according to claim 2 , wherein the homogeneous catalyst is at least one selected from the group consisting of an alkali metal compound having a hydroxyl or alkoxy group claim 2 , a bicarbonate (HCO)-containing metal compound claim 2 , and a carbonate (CO)-containing metal compound.4. The method according to claim 3 , wherein the alkali metal compound having a hydroxyl group is NaOH claim 3 , KOH claim 3 , LiOH or Ba(OH) claim 3 , andthe alkali metal compound having an alkoxy group is NaOR, KOR or LiOR (wherein, R is a substituted or unsubstituted C1-10 alkyl group).5. The method according to claim 2 , wherein the heterogeneous catalyst is a metal compound containing Mg claim 2 , Ca claim 2 , Zr claim 2 , Sn or Ti.6. The method according to claim 5 , wherein the heterogeneous catalyst further comprises at least one selected from the group consisting of an alkali metal compound claim 5 , a hydroxyl group-containing metal compound claim 5 , a bicarbonate-containing metal compound claim 5 , a carbonate-containing metal compound claim 5 , activated clay claim 5 , zeolite claim 5 , active carbon claim 5 , diatomaceous earth claim 5 , bentonite claim 5 , alumina claim 5 , silicalite claim 5 , fly ashes claim 5 , molecular sieve claim 5 , vermiculite claim 5 , perlite claim 5 , π-complex compound adsorbent claim 5 , clay and polymer resin.7. The method according to claim 1 , wherein the reaction is conducted in a batch reactor or tubular reactor.8. The method according to claim 1 , wherein the reaction is conducted at a temperature of 100 to 300° C. and a pressure of 10 to 200 atm for 1 to 20 hours claim 1 , under inert atmosphere.9. The method according to claim 1 , ...

Подробнее
28-03-2013 дата публикации

SILVER-CATALYZED SYNTHESIS OF AMIDES FROM AMINES AND ALDEHYDES

Номер: US20130079556A1
Принадлежит:

The invention provides a method for producing amides via the reaction of aldehydes and amines with oxygen adsorbed on a metallic silver or silver alloy catalyst. An exemplary reaction is shown in Scheme 1 : (I), (II), (III) 1. A method for preparing an amide comprising reacting an aldehyde and a primary or secondary amine with oxygen adsorbed on a catalyst comprising silver metal or an alloy thereof to produce the amide.4. The method of claim 2 , wherein Rand Rare methyl.5. The method of claim 1 , wherein the aldehyde is formaldehyde.6. The method of claim 1 , wherein the silver alloy is an alloy of silver and gold.7. The method of claim 1 , wherein the source of the adsorbed oxygen is oxygen gas.8. The method of claim 1 , wherein the amine is a primary amine.9. The method of claim 1 , wherein the amine is a secondary amine.10. The method of claim 1 , wherein the catalyst is promoted by a material selected from the group consisting of metal halides claim 1 , carbonates claim 1 , sulfites claim 1 , sulfates claim 1 , nitrites claim 1 , and nitrates claim 1 , transition metal oxoanions claim 1 , lanthanides claim 1 , and alkali and alkaline earth metals.11. The method of claim 1 , wherein the temperatures is from 270 to 1000 K.12. The method of claim 1 , wherein the pressure is from 0.1 atm to 5 atmospheres.13. The method of claim 1 , wherein the catalyst is carried on an inert supporting material. This application claims benefit of U.S. Provisional Application No. 61/336,673, filed Jan. 25, 2010, which is hereby incorporated by reference.This invention was made with U.S. government support under National Science Foundation awards CHE-0513936, PHY-0646094, CHE-0545335, DMR-0820484 and Department of Energy award DE-FG02-84ER13289. The U.S. Government has certain rights in the invention.The invention is in the field of synthetic organic chemistry, and relates specifically to chemical processes involving catalysis, oxidation, and amide synthesis.Amidation is a ...

Подробнее
04-04-2013 дата публикации

PROCESSES FOR PREPARATION OF POLYMORPHIC FORMS OF LACOSAMIDE

Номер: US20130085304A1
Принадлежит: RANBAXY LABORATORIES LIMITED

The present invention relates to processes for the preparation of crystalline polymorphic forms of lacosamide (Formula I), including processes for inter-conversion among such polymorphic forms. 126-. (canceled)27. A process for the preparation of crystalline polymorphic Form A of lacosamide comprising crystallizing lacosamide using an organic solvent selected from the group consisting of ethyl acetate , methanol , acetone , toluene , hexanes and mixtures thereof.281. A process of claim where in the organic solvent is a mixture of organic solvents.291. A process of claim wherein ethyl acetate is the organic solvent used at about 7 to about 12 times by volume of ethyl acetate per gram of lacosamide.303. The process of claim wherein the crystallization is performed at temperature range of about −20° C. to about 35° C.311. The process of claim wherein a mixture of organic solvents comprising ethyl acetate in an amount which is not more than about 12 times by volume per gram of lacosamide is used.321. A process of claim wherein acetone is the organic solvent.336. A process of claim wherein the crystallization is performed at temperature range of about −10° C. to about 10° C.341. A process of claim wherein methanol is the organic solvent.358. The process of claim wherein the crystallization is performed at temperature range of about −10° C. to about 20° C.362. The process of claim wherein the crystallization is performed at temperature range of about −20° C. to about 35° C.372. The process of claim wherein the mixture of organic solvents is a mixture of ethyl acetate with toluene or dichloromethane.382. The process of claim wherein the mixture of organic solvents is a mixture of methanol and hexanes.39. A process for the preparation of crystalline polymorphic Form A of lacosamide comprising suspending lacosamide in water and isolating the Form A of lacosamide.403. A process of claim , wherein an organic solvent is also used for suspending lacosamide.414. The process of ...

Подробнее
18-04-2013 дата публикации

REDUCTION OF ALDEHYDES AND KETONES TO ALCOHOLS

Номер: US20130096317A1
Принадлежит:

The embodiments described herein provide a reduction of an aldehyde or a ketone, such as a Meerwein-Ponnorf-Verley (MPV) reaction of an aldehyde or ketone. In some embodiments, the reaction occurs in the presence of Al[OC(CH)]. In some embodiments, the reaction occurs in the presence of an aprotic solvent. In some embodiments, the aldehyde or ketone is an amino aldehyde or an amino ketone wherein the amine is group is protected such that the nitrogen of the amine has no proton. Other embodiments related to compositions and compounds related to the reduction reaction, or to the preparation or use of the aldehyde, the ketone, or the resulting alcohol. 1. A method of reducing a C═O of an aldehyde or a ketone to a CH—OH of a product alcohol comprising reacting the aldehyde or ketone in the presence of Al[OC(CH)] and a reactant alcohol which comprises a carbon atom directly bonded to both a hydroxyl group and a hydrogen atom2. A method of reducing a C═O of an aldehyde or a ketone to a CH—OH of a product alcohol comprising reacting the aldehyde or ketone in the presence of: Al(OR) , a reactant alcohol comprising a carbon atom directly bonded to both a hydroxyl group and a hydrogen atom , and an aprotic solvent , wherein each Ris independently Calkyl or optionally substituted aryl.3. The method of claim 2 , wherein the aprotic solvent comprises ethyl acetate claim 2 , tetrahydrofuran claim 2 , toluene claim 2 , dichloromethane claim 2 , or an ether.4. The method of claim 2 , wherein the volume ratio of the aprotic solvent to the reactant alcohol is at least about 1:1.7. The method of claim 5 , wherein Ris COR.12. The method of claim 11 , wherein the ratio of diastereomer 1 to diastereomer 2 is at least about 0.5.13. The method of claim 11 , wherein the ratio of diastereomer 1 to diastereomer 2 has a value in the range of about 1 to about 10 claim 11 ,000. 1. Field of the InventionThe embodiments disclosed herein relate to reduction of an aldehyde or ketone, such as by ...

Подробнее
25-04-2013 дата публикации

PROCESS FOR PREPARING FORMAMIDES AND FORMIC ESTERS

Номер: US20130102807A1
Принадлежит: BASF SE

A process for preparing carboxylic acid derivatives of the formula H—(C═O)—R, R is ORor NRR, Ris optionally substituted C-C-alkyl, C-C-cycloalkyl, C-C-heterocyclyl, C-C-aryl or C-C-heteroaryl, substituents are C-C-alkyl, C-C-alkoxy, C-C-cycloalkyl or C-C-aryl; Rand Rare independently hydrogen or optionally substituted C-C-alkyl, C-Ccycloalkyl, C-C-heterocyclyl, C-C-aryl or C-C-heteroaryl, substituents are selected from the group consisting of C-C-alkyl, C-C-cycloalkyl and C-C-aryl or Rand Rtogether with the nitrogen atom form a five- or six-membered ring which optionally comprises one or more heteroatoms selected from O, S and N and bearing the substituent R, Ris hydrogen or C-C-alkyl; by reacting a reaction mixture comprising carbon dioxide, hydrogen and an alcohol of the formula R—OH or an amine of the formula NHRRin the presence of a catalyst comprising gold at a pressure from 0.2 to 30 MPa and a temperature from 20 to 200° C. in a hydrogenation reactor. 114.-. (canceled)15. A process for preparing carboxylic acid derivatives of the general formula (Ia){'br': None, 'H—(C═O)—R\u2003\u2003(Ia),'}where{'sup': 1', '2', '3, 'R is selected from the group consisting of ORand NRR, where'}{'sup': '1', 'sub': 1', '15', '5', '10', '5', '10', '5', '10', '5', '10, 'claim-text': {'sub': 1', '15', '1', '6', '5', '10', '5', '10, 'where the substituents are selected from the group consisting of C-C-alkyl, C-C-alkoxy, C-C-cycloalkyl and C-C-aryl;'}, 'Ris unsubstituted or at least monosubstituted C-C-alkyl, C-C-cycloalkyl, C-C-heterocyclyl, C-C-aryl or C-C-heteroaryl,'}{'sup': 2', '3, 'sub': 1', '15', '5', '10', '5', '10', '5', '10', '5', '10, 'claim-text': [{'sub': 1', '15', '5', '10', '5', '10, 'where the substituents are selected from the group consisting of C-C-alkyl, C-C-cycloalkyl and C-C-aryl'}, 'or', {'sup': 2', '3', '4, 'Rand Rtogether with the nitrogen atom form a five- or six-membered ring which optionally additionally comprises one or more heteroatoms selected from ...

Подробнее
25-04-2013 дата публикации

PROCESS FOR THE PREPARATION OF LACOSAMIDE

Номер: US20130102811A1
Принадлежит: SUN PHARMACEUTICAL INDUSTRIES LTD

The present invention relates to a novel and improved process for the preparation of lacosamide, wherein the process is a sequential one-pot process. 2. The process as claimed in claim 1 , wherein all the reactions of step a) to d) are carried out in dicholormethane.3. The process as claimed in claim 1 , wherein the condensation of N-Boc-D-serine with benzylamine in step a) is performed using a coupling agent claim 1 , optionally in the presence of catalytic 1-hydroxybenzitriazole4. The process as claimed in claim 3 , wherein the coupling agent is selected from the group consisting of (benzotriazole- 1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) claim 3 , is obutyl chloroformate claim 3 , N claim 3 ,N′-dicyclohexylcarbodiimide (DCC) and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide(EDC).5. The process as claimed in claim 1 , wherein methylation of compound of formula I in step b) is carried out using a methylating agent in a biphasic system in presence of a phase transfer catalyst.6. The process as claimed in claim 5 , wherein the methylating agent is selected from the group consisting of dimethyl sulfate claim 5 , methyl triflate claim 5 , and trimethyl phosphate.7. The process as claimed in claim 6 , wherein the methylating agent is dimethyl sulfate.8. The process as claimed in claim 5 , wherein the aqueous phase of the biphasic system contains an inorganic base.9. The process as claimed in claim 8 , wherein the inorganic base is selected from an alkali metal hydroxide claim 8 , carbonate and bicarbonate.10. The process as claimed in claim 5 , wherein the phase transfer catalyst is selected from a quarternized amine salt or a phosphonium salt.11. The process as claimed in claim 10 , wherein quarternized amine salt is selected from the group consisting of sulfate claim 10 , chloride or bromide salts of tetraalkylammonium; benzyltrialkylammonium halides; cetyltrialkylammonium halides and Tweens (polyoxyethylene sorbitan esters) such as Tween®20 ...

Подробнее
02-05-2013 дата публикации

PHENYL-N-ACYL DERIVATIVES OF AMINES AND AMINO ACIDS, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION AND USE THEREOF

Номер: US20130109880A1

The present invention relates to novel phenyl-N-acyl derivatives of biogenic amines and amino acids of general formula (I) as cyclooxynease inhibitors, possessing analgetic and anti-inflammatory properties and devoid of side effects in particular ulcerogeneity and pro-spasmodic actions, as well as capability to potentiate effect of other analgetics, and possessing in addition antihypoxic, antidepressant and anti-Parkinsonistic action; as well as to the processes for the preparation novel and known phenyl-N-acyl derivatives of biogenic amines, to a pharmaceutical composition and to an agent comprising compounds of general formula (I) as well as to use thereof and a method of treating. 2. The process according to claim 1 , wherein 1-1.2 equivalents of diphenylphosphorylazide and triethylamine are used.3. The process according to claim 1 , wherein as amino derivatives tyrosine or phenylalanine esters are used.43. The process according to any one of - claims 1 , wherein as an organic solvent N claims 1 ,N-dimethylformamide or ethylacetate are used.53. The process according to any one of - claims 1 , which is conducted at the temperature ranging from −25° C. to 0° C.7. The process according to claim 6 , wherein as amino derivatives tyrosine or phenylalanine esters are used. This application is a divisional of co-pending U.S. application Ser. No. 11/886,965, filed on Oct. 23, 2008, which is a U.S. National Stage application under 35 U.S.C. §371 of International Application PCT/RU2006/000139 (published as WO 2006/101422 A1), filed Mar. 24, 2006, which claims priority to Application RU 2005108492, filed Mar. 25, 2005. Benefit of the filing date of each of these prior applications is hereby claimed. Each of these prior applications is hereby incorporated by reference in its entirety.The present invention relates to the field of bioorganic chemistry and concerns novel compounds, phenyl-N-acyl derivatives of biogenic amines as well as a process for synthesis of novel and known ...

Подробнее
16-05-2013 дата публикации

METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE

Номер: US20130123505A1
Принадлежит:

A carboxamide can be produced in a high yield by a method for producing a carboxamide, for example, represented by formula (4): 1. A method for producing a carboxamide , the method comprising allowing a carboxylic acid ester , an amine , and a formamide compound corresponding to the amine to react in the presence of a metal alkoxide.3. The method according to claim 2 , wherein the step is a step of performing the reaction in a solvent.4. The method according to claim 3 , wherein the solvent is an alcohol solvent.5. The method according to claim 2 , wherein the metal alkoxide is an alkali metal alkoxide.6. The method according to claim 2 , wherein the step is a step performed under an increased pressure condition.7. The method according to claim 2 , wherein Rin each of formulae (2) claim 2 , (3) and (4) is a hydrogen atom or a C-Calkyl group.8. The method according to claim 2 , wherein Rin formula (1) is a C-Calkyl group.9. The method according to claim 3 , wherein the metal alkoxide is an alkali metal alkoxide.10. The method according to claim 3 , wherein the step is a step performed under an increased pressure condition. The present invention relates to a method for producing a carboxamide.Carboxamides are important compounds as a variety of chemical products such as active ingredients of medicines and pesticides, and electronic materials, and synthetic intermediates thereof (see, for example, WO2004/065374).In WO2004/065374 is disclosed a method in which ethyl 4,5-bis(4-methoxyphenyl)-1,3-oxazole-2-carboxylate, which is a carboxylic acid ester, is allowed to react with formamide in the presence of sodium methoxide, which is a metal alkoxide, to give 4,5-bis(4-methoxyphenyl)-1,3-oxazole-2-carboxamide, which is a carboxamide, in a yield of 71.9% (see Example 2).However, the method is not necessarily satisfactory in the yield of the carboxamide to be obtained.Thus, new methods by which a carboxamide can be produced from a carboxylic acid ester in a high yield have ...

Подробнее
16-05-2013 дата публикации

Process for preparation of lacosamide and some n-benzyl-propanamide intermediate derivatives

Номер: US20130123522A1
Принадлежит: Indoco Remedies Ltd

The present invention discloses novel process for the preparation of (2R)-2-acetamido-N-benzyl-3-methoxypropanamide of Formula I involving novel intermediates of Formula-XIX and Formula-XX.

Подробнее
16-05-2013 дата публикации

METHOD FOR SYNTHESIZING RARE EARTH METAL EXTRACTANT

Номер: US20130123534A1
Принадлежит:

A rare earth metal extractant containing, as the extractant component, dialkyldiglycol amide acid which is excellent in breaking down light rare earth elements is reacted in diglycolic acid (X mol) and an esterification agent (Y mol) at a reaction temperature of 70° C. or more and for a reaction time of one hour or more such that the mol ratio of Y/X is 2.5 or more, and is subjected to vacuum concentration. Subsequently, a reaction intermediate product is obtained by removing unreacted products and reaction residue. Then a nonpolar or low-polar solvent which is an organic solvent for forming an organic phase during solvent extraction of the rare earth metal and which is capable of dissolving dialkyldiglycol amide acid is added as the reaction solvent, and the reaction intermediate product is reacted with dialkyl amine (Z mol) such that the mol ratio of Z/X is 0.9 or more. 2. A method for synthesizing a rare earth metal extractant according to wherein the esterifying agent is selected from acetic anhydride and trifluoroacetic anhydride.3. A method for synthesizing a rare earth metal extractant according to wherein the organic solvent to form an organic phase during solvent extraction of rare earth metals is selected from the group consisting of toluene claim 1 , xylene claim 1 , hexane claim 1 , isododecane claim 1 , kerosene claim 1 , and higher alcohols.4. A method for synthesizing a rare earth metal extractant according to wherein in the step of reacting diglycolic acid with an esterifying agent claim 1 , the molar ratio of Y/X is in the range: 2.5≦Y/X≦6.5.5. A method for synthesizing a rare earth metal extractant wherein in the step of reacting the reaction intermediate product with a dialkylamine claim 1 , the molar ratio of Z/X is in the range: 0.9≦Z/X≦1.2.6. A method for synthesizing a rare earth metal extractant wherein the reaction solvent is added in such an amount that the dialkyl diglycol amic acid formed after the reactions may be present in a ...

Подробнее
16-05-2013 дата публикации

PROCESS FOR THE PREPARATION OF LACOSAMIDE

Номер: US20130123537A1
Принадлежит:

The present invention relates to an improved process for the preparation of Lacosamide of Formula (I), comprising: O-methylating a compound of Formula (V) or a compound of Formula (XX) or a compound of Formula XXII; in the presence of a methylating agent and a base to produce Lacosamide of Formula (I). 2. The process according to claim 1 , wherein the methylating agent used in O-methylation step is selected from methyl iodide claim 1 , methyl chloride claim 1 , methyl bromide claim 1 , methyl fluoride claim 1 , dimethyl sulfate claim 1 , trimethyl silyldiazomethane claim 1 , dimethyl sulfoxide (DMSO) or mixtures thereof.3. The process according to claim 1 , wherein the base used in O-methylation step is selected from sodium hydroxide claim 1 , potassium hydroxide claim 1 , sodium carbonate claim 1 , potassium carbonate claim 1 , sodium bicarbonate claim 1 , potassium bicarbonate or mixtures thereof.4. The process according to claim 1 , wherein the O-methylation is carried out in the presence of a solvent selected from tetrahydrofuran (THF) claim 1 , dichloromethane (MDC) claim 1 , dimethyl sulfoxide (DMSO) claim 1 , acetonitrile (MeCN) claim 1 , ethyl acetate claim 1 , acetone claim 1 , monoglyme claim 1 , diglyme or mixtures thereof.5. The process according to claim 1 , wherein the O-methylation is optionally carried out in the presence of a phase transfer catalyst (PTC) selected from tetraethylammonium-p-toluenesulfonate claim 1 , tetrapropylammonium trifluoromethane sulfonate claim 1 , tetraphenylphosphonium hexafluoroantimonate claim 1 , acetylpyridinium bromide claim 1 , triphenylmethyl triphenylphosponium chloride claim 1 , benzyltriethylammonium chloride claim 1 , benzyltrimethylammonium chloride claim 1 , benzyltriphenylphosphonium chloride claim 1 , benzytributylammonium chloride claim 1 , butyltriethylammonium bromide claim 1 , butyltriphenylphosphonium bromide claim 1 , cetyltrimethyl ammonium bromide claim 1 , cetyltrimethyl ammonium chloride claim 1 , ...

Подробнее
23-05-2013 дата публикации

NOVEL CATIONIC AMPHIPHILES WITH MANNOSE-MIMICKING HEAD-GROUPS AND A PROCESS FOR THE PREPARATION THEREOF

Номер: US20130129758A1

The present invention discloses novel cationic amphiphiles containing mannose-mimicking shikimic and quinic acid head-groups and a process for preparing cationic amphiphiles with mannose-mimicking polar head-groups such as, shikimic and quinic acids. The findings described herein also demonstrate that compounds of the present invention can target model DNA vaccines to antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs), via mannose receptors expressed on the cell surface of APCs. The cationic amphiphiles disclosed herein show enhanced cellular and humoral immune response compared to their mannosyl counterpart in dendritic cell (DC, the most professional APC) based genetic immunization in mice. Cationic amphiphiles with mannose-mimicking quinic and shikimic acid head-groups described in the present invention are likely to find future applications in the field of genetic immunization. 3. The cationic amphiphile of claim 1 , wherein lipophilic Rand Rmoiety is selected from the group consisting of saturated C-Calkyl groups and unsaturated C-Calkenyl groups containing 1 claim 1 , 2 or 3 double bonds.5. The process of claim 4 , wherein saturated or unsaturated aliphatic hydrocarbon chains of said amine have 8-22 carbon atoms.6. The process of claim 4 , wherein the polar aprotic solvent used in step (a) is selected from the group consisting of dichloro methane (DCM) claim 4 , dimethyl formamide (DMF) claim 4 , dimethylsulfoxide claim 4 , pyridine claim 4 , and triethyl amine.7. The process of claim 4 , wherein quaternization of the intermediate hydrophobic amide obtained in step (a) is carried out at a temperature between 25-30° C.8. The process of claim 4 , wherein the organic solvent used as polar eluent in step (c) is selected from the group consisting of methanol claim 4 , ethanol claim 4 , chloroform claim 4 , dichloro methane and ethyl acetate.9. The process of claim 4 , wherein the halide ion exchange resins used in step (c) is selected ...

Подробнее
23-05-2013 дата публикации

PROCESSES AND INTERMEDIATES FOR PREPARING STERIC COMPOUNDS

Номер: US20130131359A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

This invention relates to processes and intermediates for the preparation of an alpha-amino beta-hydroxy acid of Formula 1 2. The process of claim 1 , wherein R claim 1 , is C-Calkyl claim 1 , R′is H and R′is —NHRwherein Ris C-Calkyl or C-Ccycloalkyl.3. The process of claim 2 , wherein Ris propyl and Ris cyclopropyl.5. The process of claim 4 , wherein the aminating reagent is an azide salt and the intermediate azido compound is reduced by hydrogenation.7. The process of claim 6 , wherein the oxidizing reagent is t-butyl hydroperoxide.8. The process of claim 6 , wherein the oxidizing reagent includes a chiral reagent.9. The process of claim 8 , wherein the oxidizing reagent is a mixture of samarium (III) isopropoxide claim 8 , triphenyl arsine oxide claim 8 , S-(−)1 claim 8 ,1′-bi-2-naphthol and 4 Å molecular sieves.10. The process of claim 6 , wherein the oxidizing reagent is urea-hydrogen peroxide in the presence of trifluoroacetic anhydride.11. The process of claim 6 , wherein R′is —OE.12. The process of claim 6 , wherein Ris —NHR.13. The process of claim 11 , further comprising hydrolyzing the compound of Formula ii to give an acid and then converting the acid to an amide compound of Formula ii wherein R′is —NHR.15. The process of claim 14 , wherein the compound of Formula 1 is (2S claim 14 ,3S)-3-amino-N-cyclopropyl-2-hydroxyhexanamide.16. The process of claim 14 , wherein the organic acid is L-tartaric acid.17. The process of claim 14 , wherein the organic acid is deoxycholic acid.18. A compound which is N-cyclopropyl-3-propyloxirane-2-carboxamide.19. A compound which is N-cyclopropyl-3-propyloxirane-2-carboxamide.20. A compound which is 3-azido-N-cyclopropyl-2-hydroxyhexanamide.21. A compound which is 3-amino-N-cyclopropyl-2-hydroxyhexanamide claim 14 , L-tartaric acid salt.22. A compound which is 3-amino-N-cyclopropyl-2-hydroxyhexanamide claim 14 , deoxycholic acid salt. This application claims the benefits of U.S. Provisional Application Ser. No. 60/782,976, ...

Подробнее
23-05-2013 дата публикации

Metal Complex Compound and Process for Producing Amides Utilizing the Metal Complex Compound

Номер: US20130131366A1

A catalyst contains a metal complex compound represented by the following general formula (I). In the formula (I), M is a metal ion such as ruthenium, Lis a cyclic or acyclic, neutral or minus 1-valent unsaturated hydrocarbon group of 1 to 30 carbon atoms which may have a substituent, Land Lare each independently chlorine or the like, and Lis a compound bonded to M through phosphorus or arsenic and represented by the following general formula (IIa) or (IIb). In the formulas (IIa) and (IIb), E is phosphorus or arsenic, Yis oxygen or sulfur, Y, Yand Yare each independently a hydrogen atom, an aryl group or the like, and H is a hydrogen atom. 3. The hydration catalyst as claimed in claim 1 , wherein Lis cyclic diene claim 1 , triene or tetraene of 1 to 30 carbon atoms which may have a substituent and is a neutral or minus 1-valent unsaturated hydrocarbon group.4. The hydration catalyst as claimed in claim 1 , wherein Lis acyclic diene claim 1 , triene or tetraene of 1 to 30 carbon atoms which may have a substituent and is a neutral or minus 1-valent unsaturated hydrocarbon group.5. The hydration catalyst as claimed in claim 1 , wherein the compound represented by the general formula (IIa) or (IIb) is any one of secondary phosphine oxide claim 1 , an aliphatic phosphoric acid ester claim 1 , an aliphatic phosphorous acid ester claim 1 , an aromatic phosphoric acid ester and an aromatic phosphorous acid ester of 1 to 30 carbon atoms which may have a substituent.6. The hydration catalyst as claimed in claim 1 , wherein the compound represented by the general formula (IIa) or (IIb) is any one of diarylphosphine oxide which may have a substituent claim 1 , dialkylphosphine oxide which may have a substituent claim 1 , secondary phosphine oxide having a phenyl group which may have a substituent and having an alkyl group which may have a substituent claim 1 , a phosphorous acid dialkyl ester of 1 to 30 carbon atoms claim 1 , a phosphorous acid diphenyl ester which may have a ...

Подробнее
23-05-2013 дата публикации

Process For The Preparation Of Contrast Agents

Номер: US20130131382A1
Принадлежит: BRACCO IMAGING S.P.A.

The present invention relates to a process for the preparation of 5-[(2-hydroxyacyl)amino]-2,4,6-triiodo-1,3-benzendicarboxamidic derivatives comprising the Smiles rearrangement of a suitable precursor, by contact of an aqueous solution of this latter with an anion exchanger solid phase. 4. The process according to claim 1 , wherein the anion exchanger solid phase is a weak anion exchanger resin or a strong anion exchanger resin.5. The process according to any one of or claim 1 , wherein the anion exchanger solid phase is selected from: Amberlite® IRA 400 and Purolite® A830.6. The process according to wherein the aqueous solvent is water.7. The process according to claim 1 , wherein the pH of the reaction is comprised from 6 to 9.9. The process according to claim 8 , wherein the compound of formula (3) is:(R)-2-[[(4-nitrophenyl)sulfonyl)]oxy]propanamide; or2-[[(4-notrophenyl)sulfonyl)]oxy]ethanamide.10. The process according to any one of or claim 8 , wherein the solvent is a mixture of water/dioxane in a ratio of 3:1 by weight. The present invention relates in general to a process for the preparation of 5-[(2-hydroxyacyl)amino]-2,4,6-triiodo-1,3-benzendicarboxamidic derivatives, useful as contrast agents in diagnostic techniques.Contrast agents or contrast media, are substances that can alter the way in which a region is analyzed in medical imaging. In particular, they are able to change the contrast of an organ, an injury, or any other surrounding structure, to make visible such details that otherwise would be difficult to detect or appreciate.Contrast agents are primarily used in the radiological or in the nuclear magnetic resonance diagnostic fields. Depending on the field of application, these derivatives present structural features, such as, in the case of molecules useful as contrast agents for X-rays analysis, the presence of one or more atom with high atomic number (e.g. iodine or barium). Iopamidol (N,N′-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2S)(2- ...

Подробнее
06-06-2013 дата публикации

METHOD AND SYSTEM FOR PRODUCING GRAPHENE AND FUNCTIONALIZED GRAPHENE

Номер: US20130140495A1
Автор: Beall Gary W.
Принадлежит: NATIONAL NANOMATERIALS, INC.

This disclosure includes a process that unexpectedly can produce very inexpensive graphene, functionalized graphenes, and a new compound called graphenol in particulate or dispersions in solvents. The process can also produce graphene layers on metallic and nonmetallic substrates. Further, the graphenol, functionalized graphenes, and graphene can be utilized to form nanocomposites that yield property improvements exceeding anything reported previously. 1. A process for making graphenol or functionalized graphenes , said processes comprising the steps of:providing a carbonaceous material;extracting a humic acid solution from said carbonaceous material via a basic solution, said basic solution having a hydroxide concentration of at least approximately 0.005 moles per liter; and placing said humic acid solution in a pressure reactor;', 'adding a hydrogenation catalyst to said humic acid solution;', 'purging said pressure reactor with an inert gas;', 'charging said pressure reactor with hydrogen gas;', 'heating said humic acid solution; and', 'removing said hydrogenation catalyst from said humic acid solution,, 'chemically reducing at least one of a carbonyl group portion and a carboxylic acid group portion of said humic acid solution, said step of chemically reducing comprising the steps ofthereby producing a solution containing graphenol.2. The process of claim 1 , wherein said carbonaceous material comprises lignite or peat.3. The process of claim 1 , wherein said carbonaceous material comprises leonardite.4. The process of claim 3 , wherein said basic solution is chosen from the group consisting of sodium hydroxide claim 3 , potassium hydroxide claim 3 , and ammonium hydroxide.5. The process of claim 3 , wherein said basic solution comprises ammonium hydroxide claim 3 , and further comprising the step of removing said ammonium hydroxide by heating after said step of chemically reducing said at least one of a carbonyl group portion and a carboxylic acid group portion ...

Подробнее
06-06-2013 дата публикации

PROCESSES FOR PRODUCING DIAMINOBUTANE (DAB), SUCCINIC DINITRILE (SDN) AND SUCCINAMIDE (DAM)

Номер: US20130144028A1
Принадлежит:

Processes include providing a clarified diammonium succinate (DAS)- or monoammonium succinate (MAS)- containing fermentation broth; distilling the broth of an overhead that includes water and ammonia, and a liquid bottoms that includes SA, and at least about 20 wt % water; cooling the bottoms to a temperature sufficient to cause the bottoms to separate into a liquid portion in contact with a solid portion that is substantially pure SA; separating the solid portion from the liquid portion; and converting the solid portion to produce nitrogen containing compounds such as diamino butane (DAB), succinic dinitrile (SDN), succinic amino nitrile (SAN) or succinamide (DAM) and downstream products. 1. A process for making nitrogen containing compounds of SA comprising:(a) providing a clarified DAS-containing fermentation broth;(b) distilling the broth under super atmospheric pressure at a temperature of >100° C. to about 250° C. to form an overhead that comprises water and ammonia, and a liquid bottoms that comprises SA, and at least about 20 wt % water;(c) cooling and/or evaporating the bottoms to attain a temperature and composition sufficient to cause the bottoms to separate into a liquid portion and a solid portion that is substantially pure SA;(d) separating the solid portion from the liquid portion;(e) (1) contacting at least as part of the solid portion with hydrogen and an ammonia source in the presence of at least one hydrogenation catalyst to produce DAB, (2) dehydrating at least part of the solid portion to produce SDN or (3) dehydrating at least part of the solid portion to produce DAM; and(f) recovering the DAB, SDN or DAM.2. A process for making nitrogen containing compounds of SA comprising:(a) providing a clarified DAS-containing fermentation broth;(b) adding an ammonia separating and/or water azeotroping solvent to the broth;(c) distilling the broth at a temperature and pressure sufficient to form an overhead that comprises water and ammonia, and a liquid ...

Подробнее
20-06-2013 дата публикации

Method of preparing ethacrynic amide derivatives and application thereof

Номер: US20130156701A1
Принадлежит: National Tsing Hua University NTHU

The present invention provides a method for preparing [ 18 F]—N-(4-fluorobutyl)ethacrynic amide which is prepared from radiofluorination and deprotection of the precursor tosylate N-Boc-N-[4-(toluenesulfonyloxy)-butyl)ethacrynic amide], obtained from ethacrynic acid via 6-step synthesis in 39% yield, in a radiochemical yield of 44%, aspecific activity of 48 GBq/μmol and radiochemical purity of 98%. The present invention further provides a composition for positron emission tomography (PET) of an animal models of a tumor liver or a liver disease, comprising [ 18 F]—N-(4-fluorobutyl)ethacrynic amide and a pharmaceutically acceptable carrier.

Подробнее
27-06-2013 дата публикации

AMINE ADDUCTS, DERIVATIVES THEREOF, METHODS FOR MAKING SUCH ADDUCTS AND DERIVATIVES, AND METHODS FOR USING SUCH ADDUCTS AND DERIVATIVES

Номер: US20130161014A1
Принадлежит: Rhodia Operations

An amine adduct is made by (1) forming an addition intermediate by heating a mixture comprising at least one diene and at least one unsaturated fatty acyl compound, and reacting the addition intermediate with a diamine to form the amine adduct, or by (2) reacting at least one unsaturated fatty acyl compound with at least one diamine to form an amine intermediate, and heating a mixture of the amidoamine intermediate and at least one diene to form the amine adduct, or by (3) reacting at least one unsaturated fatty tertiary amine compound with at least at least one diene to form the amine adduct. A surfactant composition is derived from the amine adduct and is particularly useful in a method for enhancing the recovery of oil from a reservoir having a production wellbore, comprising introducing an aqueous flooding fluid into the reservoir at one or more locations different from the location of the production wellbore, said fluid comprising the surfactant composition and recovering the oil through the production wellbore. 1. An amine adduct , comprising the product obtained by: '(b) reacting the addition intermediate with a diamine to form the amine adduct, or', '(1)(a) forming an addition intermediate by heating a mixture comprising at least one diene and at least one unsaturated fatty acyl compound, and'} '(b) heating a mixture of the amidoamine intermediate and at least one diene to form the amine adduct, or', '(2)(a) reacting at least one unsaturated fatty acyl compound with at least one diamine to form an amidoamine intermediate, and'}(3) reacting at least one unsaturated fatty tertiary amine compound with at least at least one diene to form the amine adduct.2. The amine adduct of wherein the adduct is an amidoamine product claim 1 , obtained by: '(b) reacting the addition intermediate with a diamine to form the amidoamine product, or', '(1)(a) forming an addition intermediate by heating a mixture comprising at least one diene and at least one unsaturated fatty acyl ...

Подробнее
27-06-2013 дата публикации

Process for the Preparation of Nateglinide

Номер: US20130165686A1
Принадлежит: CIPLA LIMITED

The present invention relates to a process for the preparation of substantially pure nateglinide of formula (I), substantially free from the cis-isomer and L-enantiomer and preparation of enantiomerically pure nateglinide form B, directly from the hydrolysis of a (−)-N-(trans-4-isopropylcyclohexyl-1-carbonyl)-D-phenylalanine alkyl ester in a ketonic solvent or water or mixture thereof. 2. The process according to claim 1 , wherein Alk is methyl.3. The process according to claim 1 , wherein the hydrolysis is carried out at. a temperature ranging from 0° C. to 30° C.4. The process according claim 1 , wherein the solvent is a mixture of a ketone and water claim 1 , and the ketone:water ratio varies from 5:1 to 1:1.5. The process according to . wherein the solvent comprises acetone and water.6. The process according to claim 1 , wherein the solvent is a 1:1 v/v mixture of acetone and water claim 1 , isolation of the nateglinide comprises drying under vacuum tray driers at a temperature ranging from 70° C. to 90° C. claim 1 , and the nateglinide i.s isolated in polymorphic Form B.8. The process according to claim 8 , wherein the compound (IV) is in the form of an HCl addition salt.9. The process according to claim 7 , wherein the trans-4-isopropyl-cyclobexylcarboxylic acid of formula (III) is in molar excess relative to the compound (IV).10. The process according to claim 7 , wherein the condensing reagent is selected from the group consisting of phenylsilane claim 7 , 1 claim 7 ,1′-carbonyldiimidazole (CDI) claim 7 , benzotriazol-1-yloxytris (dimethylamino) phophonium hexafluorophosphate (BOP) claim 7 , 1-hydroxy benzotriazole hydrate (HOBO claim 7 , PyBOP (Analog of the BOP) claim 7 , 1 claim 7 ,3-dicyclohexylcarbodiimide (DCC) claim 7 , 1 claim 7 ,3-chisopropylcarbodiimide (DIC) claim 7 , N claim 7 ,N-diisopropylethylamine (DIEA) claim 7 , 4-dimethylaminopyridine (DMAP) claim 7 , 1 claim 7 ,4-dithio-L-threitol (DTT) claim 7 , N-ethyl-V-(3-dimethylaminopropyl) ...

Подробнее
04-07-2013 дата публикации

Cysteine protease inhibitors

Номер: US20130172232A1
Принадлежит: Medivir UK Ltd

Compounds of the formula I wherein R 2a and R 2b are independently H, halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl or C 1 -C 4 alkoxy, or R 2a and R 2b together with the carbon atom to which they are attached form a C 3 -C 6 cycloalkyl; R 3 is a C 5 -C 10 alkyl, optionally substituted with 1-3 substituents independently selected from halo, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy; or R 3 is a C 2 -C 4 alkyl chain with at least 2 chloro or 3 fluoro substituents; or R 3 is C 3 -C 7 cycloalkylmethyl, optionally substituted with 1-3 substituents independently selected from C 1 -C 4 alkyl, halo, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy; R 4 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino or; R 4 is Het or Carbocyclyl, either of which is optionally substituted with 1-3 substituents R 4 is Het, carbocyclyl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy; n is 1, 2 or 3; for the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Подробнее
04-07-2013 дата публикации

3-[4-(PHENYLAMINOOXALYLAMINO)PHENYL]HEX-4-YNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT

Номер: US20130172248A1
Принадлежит:

The invention relates to 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, and to physiologically compatible salts thereof. 2. A compound as claimed in claim 1 , wherein{'sub': '3', 'R1 is H, F, CH;'}{'sub': '3', 'R2 is F, CH;'}{'sub': '3', 'R3 is F, CH;'}{'sub': 3', '3, 'R4 is H, Cl, CH, CF;'}and physiologically compatible salts thereof.9. (canceled)10. A pharmaceutical composition comprising the compound of claim 1 , and a pharmaceutically acceptable carrier.11. The pharmaceutical composition as claimed in claim 10 , which comprises at least one further active ingredient.12. The pharmaceutical composition as claimed in claim 11 , which comprises claim 11 , as a further active ingredient claim 11 , one or more antidiabetics claim 11 , active hypoglycemic ingredients claim 11 , HMG-CoA reductase inhibitors claim 11 , cholesterol absorption inhibitors claim 11 , PPAR gamma agonists claim 11 , PPAR alpha agonists claim 11 , PPAR alpha/gamma agonists claim 11 , PPAR delta agonists claim 11 , fibrates claim 11 , MTP inhibitors claim 11 , bile acid absorption inhibitors claim 11 , CETP inhibitors claim 11 , polymeric bile acid adsorbers claim 11 , LDL receptor inducers claim 11 , ACAT inhibitors claim 11 , antioxidants claim 11 , lipoprotein lipase inhibitors claim 11 , ATP citrate lyase inhibitors claim 11 , squalene synthetase inhibitors claim 11 , lipoprotein(a) antagonists claim 11 , HM74A receptor agonists claim 11 , lipase inhibitors claim 11 , insulins claim 11 , sulfonylureas claim 11 , biguanides claim 11 , meglitinides claim 11 , thiazolidinediones claim 11 , alpha-glucosidase inhibitors claim 11 , active ingredients which act on the ATP-dependent potassium channel of the beta cells claim 11 , glycogen phosphorylase inhibitors claim 11 , glucagon receptor antagonists claim 11 , activators of glucokinase claim 11 , inhibitors of gluconeogenesis claim 11 , inhibitors of fructose 1 claim 11 ,6-biphosphatase claim 11 , modulators of glucose transporter 4 claim ...

Подробнее
04-07-2013 дата публикации

PROCESSES FOR PRODUCING DIAMINOBUTANE (DAB), SUCCINIC DINITRILE (SDN) AND SUCCINAMIDE (DAM)

Номер: US20130172519A1
Принадлежит: BIOAMBER S.A.S.

Processes that make nitrogen-containing compounds include converting succinic acid (SA) or monoammonium succinate (MAS) derived from a diammonium succinate (DAS)- or MAS-containing fermentation broth to produce such compounds including diaminobutane (DAB), succinic dinitrile (SDN), succinic amino nitrile (SAN), succinamide (DAM), and related polymers. 1. A process for making nitrogen containing compounds , comprising:(a) providing a clarified DAS-containing fermentation broth;(b) distilling the broth to form an overhead that comprises water and ammonia, and a liquid bottoms that comprises MAS, at least some DAS, and at least about 20 wt % water;(c) cooling and/or evaporating the bottoms, and optionally adding an antisolvent to the bottoms, to attain a temperature and composition sufficient to cause the bottoms to separate into a DAS-containing liquid portion and a MAS-containing solid portion that is substantially free of DAS;(d) separating at least part of the solid portion from the liquid portion; (2) dehydrating at least a part of the solid portion to produce SDN; or', '(3) dehydrating at least a part of the solid portion to produce DAM; and, '(e) (1) contacting the solid portion with hydrogen and optionally an ammonia source in the presence of at least one hydrogenation catalyst to produce DAB; or'}(f) recovering the DAB, SDN or DAM.2. A process for making nitrogen containing compounds , comprising:(a) providing a clarified DAS-containing fermentation broth;(b) distilling the broth to form a first overhead that includes water and ammonia, and a first liquid bottoms that includes MAS, at least some DAS, and at least about 20 wt % water;(c) cooling and/or evaporating the bottoms, and optionally adding an antisolvent to the bottoms, to attain a temperature and composition sufficient to cause the bottoms to separate into a DAS-containing liquid portion and a MAS-containing solid portion that is substantially free of DAS;(d) separating the solid portion from the ...

Подробнее
04-07-2013 дата публикации

PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH

Номер: US20130172560A1
Автор: Stranne Robert
Принадлежит: AstraZeneca AB

Presented herein are processes for making cyclopropyl amide derivatives of formula I, and/or pharmaceutically acceptable salts thereof, and intermediates associated therewith. At least one cyclopropyl amide derivative of formula I, or pharmaceutically acceptable salt thereof is useful to treat at least one histamine H3 receptor associated condition. 3. The process of claim 2 , wherein said base is sodium hydroxide.4. The process of claim 2 , wherein said peroxide is hydrogen peroxide.5. The process of claim 2 , wherein said acidic solution is an aqueous solution of sodium hydrogen sulfate.7. The process of claim 6 , wherein X is Br.8. The process of claim 6 , wherein said metal is zinc.9. The process of claim 6 , wherein said metal cyanide is zinc-(II)-cyanide.10. The process of claim 6 , wherein said catalyst is bis(tri-t-butylphosphine)palladium(0).15. The process of claim 14 , wherein said activating agent is 1 claim 14 ,1′-carbonyldiimidazole.19. The process of claim 18 , wherein the activating agent is a mixture of 1-hydroxybenzotriazole and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride.21. The process of claim 16 , wherein said acid is hydrochloric acid.23. The process of claim 17 , wherein said reducing agent is sodium triacetoxy borohydride. Presented herein are processes for making cyclopropyl amide derivatives of formula I, and/or pharmaceutically acceptable salts thereof, and intermediates associated therewith. At least one cyclopropyl amide derivative of formula I, or pharmaceutically acceptable salt thereof is useful to treat at least one histamine H3 receptor associated condition.The histamine H3 receptor is of current interest in developing new medicaments. The H3 receptor is a presynaptic autoreceptor located both in the central and peripheral nervous systems, the skin, and in organs, such as, for example, the lung, the intestine, probably the spleen, and the gastrointestinal tract. Recent evidence suggests the H3 receptor has intrinsic ...

Подробнее
04-07-2013 дата публикации

Process for Manufacture of N-acylbiphenyl alanine

Номер: US20130172572A1
Принадлежит:

A novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, in particular neutral endopeptidase (NEP) inhibitors. 2. The process according to claim 1 , wherein the alkaline conditions comprise the use of a base selected from triethylamine claim 1 , pyridine claim 1 , N-methylpyrrole claim 1 , N-methylmorpholine claim 1 , sodium bicarbonate claim 1 , sodium carbonate claim 1 , potassium bicarbonate claim 1 , potassium carbonate claim 1 , sodium acetate claim 1 , potassium acetate claim 1 , sodium propionate and potassium propionate.3. The process according to ems claim 1 , wherein the reaction is carried out at a temperature of from of from 80 deg C. to reflux.5. The process according to claim 4 , wherein the reaction is carried out at a temperature of from of from room temperature to reflux.7. The process according to claim 6 , wherein the hydrogenation conditions comprise the use of hydrogen and palladium claim 6 , preferably claim 6 , palladium on charcoal.8. A process for preparing a compound of formula (3) claim 6 , as defined in claim 6 ,comprising the steps of{'claim-ref': [{'@idref': 'CLM-00001', 'claim 1'}, {'@idref': 'CLM-00001', 'claim 1'}], 'i) preparing the compound of formula (1-a), as defined in , according to the process defined in ;'}{'claim-ref': [{'@idref': 'CLM-00004', 'claim 4'}, {'@idref': 'CLM-00004', 'claim 4'}], 'ii) preparing the compound of formula (2-a), as defined in , according to the process defined in ; and'}{'claim-ref': {'@idref': 'CLM-00006', 'claim 6'}, 'iii) obtaining the compound of formula (3), according to the process defined in .'}9. A process for preparing a compound of formula (3) claim 6 , as defined in claim 6 ,comprising the steps of{'claim-ref': [{'@idref': 'CLM-00004', 'claim 4'}, {'@idref': 'CLM-00004', 'claim 4'}], 'ii) preparing the compound of formula (2-a), as defined in , according to the process defined in ; and'}{'claim-ref': {'@idref': 'CLM-00006', ...

Подробнее
04-07-2013 дата публикации

Novel Polymers

Номер: US20130172600A1
Принадлежит: NOVARTIS AG

The invention relates to novel crosslinkable copolymers which are obtainable by (a) copolymerizing at least two different hydrophilic monomers selected from the group consisting of N,N-dimethyl acrylamide (DMA), 2-hydroxyethyl acrylate (HEA), glycidyl methacrylate (GMA), N-vinylpyrrolidone (NVP), acrylic acid (AA) and a C-C-alkoxy polyethylene glycol(meth)acrylate having a weight average molecular weight of from 200 to 1500, and at least one crosslinker comprising two or more ethylenically unsaturated double bonds in the presence of a chain transfer agent having a functional group; and (b) reacting one or more functional groups of the resulting copolymer with an organic compound having an ethylenically unsaturated group. 124-. (canceled)25. A process for manufacturing an actinically crosslinkable prepolymer , comprising:(1) obtaining a reaction mixture comprising a first hydrophilic monomer, at least one polysiloxane-containing crosslinker, a second hydrophilic monomer, and a chain transfer agent having a first functional group and present in an amount to have a desired initial concentration;(2) adjusting the temperature of the reaction mixture in order to start the polymerization reaction;(3) dosing the chain transfer agent to the reaction mixture at a rate sufficient to have a concentration comparable to the desired initial concentration until a desired total amount of the chain transfer agent is added;(4) following the completion of the chain transfer agent dosing maintaining the reaction mixture at the reaction temperature in order to complete the reaction so as to obtain a copolymerization product with first functional groups; and(5) reacting an organic compound with the copolymerization product to form the crosslinkable prepolymer having ethylenically unsaturated groups, wherein the organic compound comprises an ethylenically unsaturated group and a second functional group, wherein the second functional group of the organic compound reacts with one of the ...

Подробнее
11-07-2013 дата публикации

Processes for preparing 3-benzazepines

Номер: US20130178620A1
Принадлежит: Arena Pharmaceuticals Inc

The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.

Подробнее
18-07-2013 дата публикации

ACID ADDITION SALT OF A NORTRIPTYLINE-GABA CONJUGATE AND A PROCESS OF PREPARING SAME

Номер: US20130184347A1
Принадлежит:

An acid addition salt of a nortriptyline-GABA conjugate, a novel crystalline form of a fumaric acid addition salt of a nortriptyline-GABA conjugate, and processes of preparing the forgoing are disclosed. Uses of the above-indicated forms of a nortriptyline-GABA conjugate in the treatment of CNS disorders, and in the treatment of pain in particular, are also disclosed. Further disclosed in a large-scale process of preparing a nortriptyline-GABA conjugate. 149-. (canceled)50. A fumaric acid addition salt of nortriptyline-4-aminobutyrate.51. A crystalline form of a fumaric acid addition salt of nortriptyline-4-aminobutyrate , characterized by at least one of:{'figref': {'@idref': 'DRAWINGS', 'FIG. 3'}, '(a) an X-Ray Powder Diffraction (XRPD) pattern exhibiting at least four of the peaks shown in ;'}{'figref': {'@idref': 'DRAWINGS', 'FIG. 1'}, '(b) an infrared spectrum exhibiting at least three of the absorption peaks shown in ; and'}(c) a Differential Scanning calorimetry (DSC) exhibiting an endothermic peak maximum that ranges from 155° C. to 160° C.52. The crystalline form of nortriptyline-4-aminobutyrate fumarate of claim 51 , characterized by an X-Ray Powder Diffraction (XRPD) pattern exhibiting at least six of the peaks shown in .53. The crystalline form of nortriptyline-4-aminobutyrate fumarate of claim 51 , characterized by an X-Ray Powder Diffraction (XRPD) pattern exhibiting at least seven of the peaks shown in .54. The crystalline form of nortriptyline-4-aminobutyrate fumarate of claim 51 , characterized by an X-Ray Powder Diffraction (XRPD) pattern substantially identical to the XRPD pattern shown in .55. The crystalline form of nortriptyline-4-aminobutyrate fumarate of claim 51 , characterized by an infrared spectrum exhibiting at least five of the absorption peaks shown in .56. The crystalline form of a fumaric acid addition salt of nortriptyline-4-aminobutyrate of claim 51 , characterized by an infrared spectrum exhibiting absorption peaks substantially ...

Подробнее
18-07-2013 дата публикации

PROCESS FOR PREPARATION OF 4-FLUORO-alpha-[2METHYL-L-OXOPROPYL]-gamma-OXO-N-beta-DIPHENYLBENZENE BUTANE AMIDE

Номер: US20130184493A1
Принадлежит: VIJAYASRI ORGANICS LIMITED

A process for preparation of 4-fluoro-α-[2-methyl-1-oxopropyl]-γ-oxo-N-β-diphenylbenzene butane amide also known as a diketone intermediate of atorvastatin, completely devoid of impurities 3,4-difluoro-α-[2-methyl-1-oxopropyl]-γ-oxo-n-β-diphenylbenzene butane amide; methyl, 2{-2[-(4-fluorophenyl)-2-oxo-1-phenylethyl)]}-4-methyl-3-oxo pentanoate; 1,4-bis(4-fluorophenyl)-2,3-diphenylbutane-1,4-dione, 1-(4-fluorophenyl)-2-phenyl ethanone; 1-(4-fluorophenyl)-2-phenyl ethanone and containing about 0.05% or less of 2-methyl-1-oxopropyl]-γ-oxo-N-β-diphenylbenzene butane amide. In that process the said diketone intermediate of formula 1 is obtained by maintaining temperature −25° C. to 50° C. during Friedel-Crafts acylation, in situ halogenation of formula II in presence of a solvent and nucleophilic substitution from a compound of formula III with formula IV in presence of a base. 2. The process of claim 1 , wherein said Friedel-Crafts condensation is carried out in presence of Lewis acid catalyst to afford said Formula II.3. The process of claim 2 , wherein said lewis acid catalyst is selected from the group comprising FeCl3 claim 2 , SbCl5 claim 2 , BF3 claim 2 , TiCl4 claim 2 , ZnC2 or AlCl3.4. (canceled)5. The process of claim 1 , wherein the inert solvent in step (b) is methylene chloride.6. The process of claim 1 , wherein said halogen is selected from the group consisting of bromine and chlorine.7. The process of claim 1 , wherein said base for nucleophilic substitution of said formula III is eitherone or more inorganic salts selected from the group comprising sodium carbonate, potassium carbonate or cesium carbonate; orone or more organic bases selected from the group comprising triethyl amine or diisopropylethylamine.8. The process of claim 1 , wherein said solvent for nucleophilic substitution of said formula III is selected from the group comprising tetrahydrofuran claim 1 , 1 claim 1 ,2-dimethoxy ethane claim 1 , methylene chloride claim 1 , ethyl acetate claim ...

Подробнее
25-07-2013 дата публикации

NOVEL COMPOUND ACCELERATING SECRETION OF HUMAN-DERIVED ANTI-MICROBIAL PEPTIDE, METHOD FOR PREPARING SAME, AND COMPOSITION HAVING SAME AS ACTIVE INGREDIENT

Номер: US20130190397A1
Принадлежит: NEOPHARM CO., LTD.

Disclosed is a compound having an acceleration effect on the secretion of human β-defensin, LL-37, which is a human-derived anti-microbial peptide, a method for preparing same, and a composition for accelerating the secretion of anti-microbial peptide having same as an active ingredient, and the compound and the composition using same of the present invention enhance the anti-microbial effect and the immunity control effect that the anti-microbial peptide has in the body by accelerating the secretion of the anti-microbial peptide in the body. 18-. (canceled)10. The new compound of claim 9 , wherein the antimicrobial peptides are human β-defensin-2 claim 9 , β-defensin-3 claim 9 , or LL-37.14. The composition of claim 13 , wherein the compound as an active ingredient is contained at 0.001-90 wt %.15. The composition of claim 13 , wherein the composition for promoting secretion of human antimicrobial peptides in vivo is a formulation selected from the group consisting of a liquid phase claim 13 , an emulsion phase claim 13 , a suspension phase claim 13 , a cream phase claim 13 , an ointment phase claim 13 , a gel phase claim 13 , a jelly phase claim 13 , and a spray phase.16. The composition of claim 13 , wherein the composition for promoting secretion of human antimicrobial peptides in vivo is a formulation selected from the group consisting of a tablet claim 13 , a liquid claim 13 , a powder claim 13 , and an injection. This application is a continuation application of PCT International Application No. PCT/KR2010/005759 filed Aug. 27, 2010, the contents of which are incorporated herein by reference in their entirety.The following disclosure relates to a compound for promoting the secretion of human antimicrobial peptides, and more particularly, to a new compound for inducing direct or indirect expression of human β-defensin-2 and -3 and LL-37, which are human antimicrobial peptides, a method for preparing the same, and a composition comprising the same as an active ...

Подробнее
25-07-2013 дата публикации

Process for the preparation of amino acid derivatives

Номер: US20130190533A1
Принадлежит: UCB PHARMA GMBH

The present invention relates to a process of manufacture of compounds of formula (B) wherein R 1 , R 2 and R 3 are as defined for compounds of formula (A), which process comprises hydrogenation of compounds of general formula (A). In particular, the present invention relates to an improved process for the manufacture of Lacosamide (LCM), (R)-2-acetamido-N-benzyl-3-methoxypropion-amide (B1), which is useful as an anticonvulsive drug.

Подробнее
08-08-2013 дата публикации

PROCESSES FOR REDUCING IMPURITIES IN LACOSAMIDE

Номер: US20130204042A1
Принадлежит: RANBAXY LABORATORIES LIMITED

The present invention relates to processes for reducing impurities in lacosamide during the preparation of lacosamide. The invention provides processes for minimizing or removing impurities such as (2R)-2-(acetylamino)-3-(benzylamino)-3-oxopropyl acetate of Formula II or (2R)-2-propanoylamino-N-benzyl-3-methoxypropionamide of Formula III in lacosamide. 2. The process of wherein the lacosamide prepared is substantially free of Impurity-A and/or Impurity-B.4. The process of wherein the lacosamide prepared is substantially free of Impurity-A and/or Impurity-B.5. A process for reducing the content of “Impurity-A” in lacosamide during the preparation of lacosamide that comprises the step of treating D-serine with a protecting reagent wherein the number of moles of the protecting reagent is less than the number of moles of D-serine.6. The process of wherein the lacosamide prepared is substantially free of Impurity-A.8. The process of wherein lacosamide prepared is substantially free of Impurity-B.9. Lacosamide substantially free of Impurity-A and Impurity-B.10. Lacosamide substantially free of Impurity-A.11. Lacosamide substantially free of Impurity-B. The present invention relates to processes for reducing impurities in lacosamide during preparation of lacosamide. The invention provides processes for minimizing or removing impurities such as (2R)-2-(acetylamino)-3-(benzylamino)-3-oxopropyl acetate of Formula II or (2R)-2-propanoylamino-N-benzyl-3-methoxypropionamide of Formula III in lacosamide.Lacosamide (SPM 927, also referred to as harkoseride or ADD 234037), is chemically (R)-2-acetamido-N-benzyl-3-methoxypropionamide and represented by Formula I. It has been reported to be effective for the treatment of pain, epilepsy, fibromyalgia syndrome, osteoarthritis and migraine. It is also known to be useful for the treatment of CNS disorders in humans.Lacosamide is available in the United States market as solution and tablet dosage forms with proprietary name of Vimpat®. ...

Подробнее
15-08-2013 дата публикации

Novel esteramide compounds, methods for preparing same, and uses thereof

Номер: US20130210634A1
Принадлежит: Rhodia Operations SAS

An esteramide compound of the following formula (I): R 1 OOC-A-CONR 2 R 3   (I) is described, wherein: A is a covalent bond or a methylene group —CH 2 —; R 1 is an optionally substituted, saturated or unsaturated aliphatic or cycloaliphatic hydrocarbon group including from 5 to 36 carbon atoms, R 2 and R 3 , either identical or different, are groups selected from a hydrogen atom, and optionally substituted hydrocarbon groups, preferably including from 1 to 36 carbon atoms, and R 2 and R 3 not being simultaneously hydrogen atoms. Also described, are applications for using the esteramide compound, notably as a solvent.

Подробнее
15-08-2013 дата публикации

TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS

Номер: US20130210918A1
Принадлежит: The Scripps Research Institute

The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors. 1. A method of treating or delaying the onset of Friedreich's ataxia in a mammal comprising administering to the mammal a histone deacetylase inhibitor in an amount effective to inhibit a histone deacetylase in the mammal.2. The method of claim 1 , wherein the histone deacetylase inhibitor is administered to the mammal in an amount effective to increase the level of histone acetylation in the mammal.3. The method of claim 1 , wherein the histone deacetylase inhibitor is administered to the mammal in an amount effective to increase frataxin mRNA in the mammal.4. The method of claim 1 , wherein the histone deacetylase inhibitor interacts with a class I histone deacetylase.5. The method of claim 4 , wherein the class I histone deacetylase is selected from the group consisting of a histone deacetylase 1 claim 4 , histone deacetylase 2 claim 4 , histone deacetylase 3 claim 4 , histone deacetylase 8 claim 4 , and a histone deacetylase that has a deacetylase domain exhibiting from 45% to 93% identity in amino acid sequence to deacetylase 1 claim 4 , histone deacetylase 2 claim 4 , histone deacetylase 3 claim 4 , and histone deacetylase 8.6. The method of claim 4 , wherein the class 1 histone deacetylase is selected from the group consisting of a histone deacetylase 1 claim 4 , histone deacetylase 2 claim 4 , histone deacetylase 3 claim 4 , and histone deacetylase 8.7. The method of claim 4 , wherein the class I histone deacetylase is a histone deacetylase 1.8. The method of claim 4 , wherein the class I histone deacetylase is a histone deacetylase 2.9. The method of claim 4 , wherein the class I histone deacetylase is a histone deacetylase 3.10. The method of claim 4 , wherein the class I histone deacetylase is a histone deacetylase 8.11. The method of claim 1 , wherein the mammal has a GAA triplet repeat in intron 1 of the frataxin gene.13. The method of claim 12 , wherein ...

Подробнее
15-08-2013 дата публикации

NOVEL CRYSTALLINE FORMS OF (1S,2R)-2-(AMINO METHYL)-N,N-DIETHYL-1-PHENYL CYCLOPROPANE CARBOXAMIDE

Номер: US20130210919A1
Принадлежит:

The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described. 1. A crystalline form of (1S ,2R)-2-(amino methyl)-N ,N-diethyl-1-phenyl cyclopropane carboxamide having an X-ray powder diffraction pattern comprising characteristic peaks at 12.0 , 20.1 and 22.5±0.2 degrees 2θ.2. The crystalline form of claim 1 , wherein the X-ray powder diffraction pattern further comprises a characteristic peak at 32.7±0.2 degrees 2θ.3. The crystalline form of claim 1 , wherein the X-ray powder diffraction pattern further comprises a characteristic peak at 6.0±0.2 degrees 2θ.4. A crystalline form of (1S claim 1 ,2R)-2-(amino methyl)-N claim 1 ,N-diethyl-1-phenyl cyclopropane carboxamide having an X-ray powder diffraction pattern comprising characteristic peaks at 6.0 claim 1 , 12.0 and 20.1±0.2 degrees 2θ.5. The crystalline form of claim 4 , wherein the X-ray powder diffraction pattern further comprises a characteristic peak at 22.5±0.2 degrees 2θ.6. The crystalline form of having a melting endotherm at about 200° C. as determined by differential scanning calorimetry.7. The crystalline form of having a Raman spectrum comprising characteristic peaks at about 695 claim 4 , about 735 and about 1435 cm.8. The crystalline form of having an X-ray diffraction pattern further comprising d spacing peaks at 4.0 and 4.4±0.2 Å.9. A pharmaceutical composition comprising the crystalline form of and a pharmaceutically acceptable carrier.10. A method of treating a disorder that can be managed by inhibition of norepinephrine and serotonin reuptake in a patient in need thereof claim 1 , by administering to said patient an effective amount of a pharmaceutical compositions that comprises the crystalline form of .11. A pharmaceutical composition comprising the crystalline form of and a pharmaceutically acceptable ...

Подробнее
15-08-2013 дата публикации

Process for the Preparation of Prostaglandin Analogues

Номер: US20130211128A1
Принадлежит: SCINOPHARM TAIWAN LTD.

A process for preparing a prostaglandin analogue comprising a step of converting a compound of formula (8′): 2. The process of wherein the compound of formula (11) is travoprost.3. The process of wherein the compound of formula (11) is bimatoprost.5. The process of wherein the step (b) comprising steps of:(1) reducing the ketone group of compound of formula (10B);(2) deprotecting the reduced form of the compound of formula (10B); and(3) reacting the resultant compound of step (2) with ethylamine to give the bimatoprost.6. The process of wherein the step (3) is conducted in the presence of 40 to 80% v/v ethylamine in methanol.7. The process of wherein the step (b) comprising steps of:(1) reducing the ketone group of compound of formula (10B);(2) reacting the reduced compound of step (1) with ethylamine; and(3) deprotecting the resultant compound of step (2) to give the bimatoprost.8. The process of wherein the step (2) is conducted in the presence of 40 to 80% v/v ethylamine in methanol. This application is a divisional of U.S. patent application Ser. No. 12/905,439 which was filed with the U.S. Patent and Trademark Office on Oct. 15, 2010, which is a divisional of U.S. patent application Ser. No. 12/421,185 which was filed with the U.S. Patent and Trademark Office on Apr. 9, 2009, which claims priority from U.S. Provisional Patent Application Ser. No. 61/123,527 which was filed on Apr. 9, 2008. The entire content of these related applications is explicitly incorporated herein as reference.1. Field of the InventionThe present application is directed to intermediates for preparing prostaglandin analogues and processes for preparing prostaglandin analogues and intermediates thereof.2. Description of the Related ArtNatural prostaglandins have a unique structure based on prostanoic acid and exhibit a broad range of physiological activities even when present in extremely small amounts, attracting interest of many organic synthetic chemists. Therefore, various processes to ...

Подробнее
15-08-2013 дата публикации

Process for Preparing Esteramide Compounds

Номер: US20130211129A1
Принадлежит: Rhodia Operations

The present invention concerns a process for preparing esteramide compounds. More particularly, the invention relates to a process for preparing esteramide compounds by reaction between a diester and an amine, in the presence of a basic compound, wherein the basic compound and the amine in gaseous form are co-added to the diester, the reaction being conducted at a temperature of 30° C. or higher.

Подробнее
15-08-2013 дата публикации

METERING RING

Номер: US20130211140A1
Принадлежит:

The present invention relates to an apparatus for metering flowable media or gases, and to the use thereof. 1. A method for carrying out a chemical reaction by continuously feeding reactants in a tubular or loop reactor , comprising metering one of the reactants through one or more metering rings located at one or more metering sites in the tubular or loop reactor , wherein at the point of metered addition , said one of the reactants is rapidly mixed and reacted with remaining reactants.2. The method of claim 1 , wherein the chemical reaction is the preparation of methacrylamide by hydrolysis of acetone cyanohydrin with concentrated sulfuric acid.3. The method of claim 2 , wherein the acetone cyanohydrin is the reactant that is fed through the one or more metering rings.4. The method of claim 2 , wherein the acetone cyanohydrin exits through the one or more metering rings in the form of a fine distribution of droplets.5. The method of claim 2 , wherein the sulfuric acid is the reactant that is fed through the one or more metering rings.6. The method of claim 2 , wherein the temperature of at least one metering ring is controlled.7. The method of claim 2 , wherein metered addition is carried out at elevated pressure.8. The method of claim 2 , wherein at least one of the metering rings has a peripheral distribution chamber.9. The method of claim 2 , wherein at least one of the metering rings has an inner wall that is permeated by a plurality of injection channels.10. The method of claim 2 , wherein at least one of the metering rings enables supply and fine distribution of the reactants over the entire circumference or cross section of the reactor.11. The method of claim 2 , wherein the metering sites project through tubes into the interior of the reactor.12. The method of claim 11 , wherein the tubes are of different length.13. The method of claim 2 , wherein the concentrated sulfuric acid is used in a molar excess to the acetone cyanohydrin claim 2 , and a reaction ...

Подробнее
22-08-2013 дата публикации

SYNTHESIS OF CYCLOHEXANE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS

Номер: US20130216486A1
Принадлежит: The Procter & Gamble Company

The present invention provides synthetic routes for preparing various isomers of cyclohexane-based coolants, such as menthyl esters and menthanecarboxamide derivatives, in particular those substituted at the amide nitrogen, for example with an aromatic ring or aryl moiety. Such structures have high cooling potency and long lasting sensory effect, which make them useful in a wide variety of consumer products. One synthetic route involves a copper catalyzed coupling of a primary menthanecarboxamide with an aryl halide, such reaction working best in the presence of potassium phosphate and water. Using this synthetic route, specific isomers can be prepared including the menthanecarboxamide isomer having the same configuration as l-menthol and new isomers such as a neoisomer having opposite stereochemistry at the carboxamide (C-1) position. The neoisomer unexpectedly has potent and long lasting cooling effect. Preparation schemes for neoisomers of other menthyl derivatives which are useful as coolants, including esters, ethers, carboxy esters and other N-substituted carboxamides are also provided. 2. The process of wherein the reaction is conducted in the presence of potassium phosphate and the copper catalyst is a copper halide.3. The process of wherein the copper halide is copper (I) iodide.4. The process of wherein the primary menthane carboxamide is prepared by reacting a menthane acid chloride with ammonia under aqueous conditions.5. The process of wherein the menthane carboxamide is prepared by hydrolysis of a corresponding menthane nitrile.6. The process of wherein the stereochemistry of the starting menthane carboxamide is maintained through the coupling reaction with aryl halide to produce the N-substituted menthane carboxamide.7. The process of wherein (1S claim 6 ,2S claim 6 ,5R)-menthane carboxamide is reacted with aryl halide to produce neoisomers having 1S claim 6 ,2S claim 6 ,5R configuration of N-aryl substituted menthane carboxamide.8. A process for ...

Подробнее
29-08-2013 дата публикации

Fluoroalkylation Methods And Reagents

Номер: US20130225815A1
Принадлежит: University of Illinois

A method of forming a fluorinated molecular entity includes reacting in a reaction mixture an aromatic halide, copper, a fluoroalkyl group, and a ligand. The aromatic halide includes an aromatic group and a halogen substituent bonded to the aromatic group. The ligand includes at least one group-V donor selected from phosphorus and an amine. The overall molar ratio of copper to aromatic halide in the reaction mixture is from 0.2 to 3. The method further includes forming a fluoroalkylarene including the aromatic group and the fluoroalkyl group bonded to the aromatic group. A composition, which may be used in the method, consists essentially of copper, the fluoroalkyl group, and the ligand, where the molar ratio of copper to the fluoroalkyl group is approximately 1.

Подробнее
29-08-2013 дата публикации

METHOD FOR PREPARING ALISKIREN AND ITS INTERMEDIATES THEREOF

Номер: US20130225841A1

A method for preparing Aliskiren and intermediate thereof, which comprises the following steps: reacting 4-bromo-1-methoxy-2-(3-methoxypropoxy)benzene with magnesium isopropyl chloride and n-BuLi to obtain the compound of formula XXII; reacting the product of methylsulfonylation of the compound of formula XIX with anhydrous LiBr to obtain the compound of formula XXI; obtaining the intermediate of Aliskiren shown as formula XV by reacting the compound of formula XXII with the compound of formula XXI in an ether as the solvent and in the presence of a catalyst containing iron; then reacting the compound of formula XV with the compound of formula VII to obtain the compound of formula XXIII, following removing Rfrom the amino group and obtaining Aliskiren shown as formula I. 2. The method according to wherein the ether class solvent in step (1) is one selected from diethyl ether claim 1 , tetrahydrofuran or 1 claim 1 ,2-dimethoxyethane.3. The method according to wherein the inert solvent in step (2) is methylene chloride or tetrahydrofuran.4. The method according to wherein the ketone class solvent in step (3) is acetone or 2-butanone; and the molar ratio between lithium bromide and the compound of formula XX is 1.1 to 5.5. The method according to wherein the said ether class solvent in step (4) is either one or mixture of any two selected from diethyl ether claim 1 , tetrahydrofuran or 1 claim 1 ,2-dimethoxyethane; the said iron-contained catalyst is selected from iron(III) acetylacetonate or Iron(III) chloride; and the reaction temperature is −15° C.˜20° C.7. The method according to for preparing the Aliskiren compound of formula I claim 6 , wherein the reaction in step (a) between the compound of formula XV and the compound of formula VII to obtain the compound of formula XXIII is implemented in an inert solvent.8. The method according to for preparing the Aliskiren compound of formula I claim 7 , wherein the inert solvent is one selected from dioxane or toluene.9. ...

Подробнее
29-08-2013 дата публикации

Crosslinked Polymers with the Crosslinker as Therapeutic for Sustained Release

Номер: US20130225857A1
Принадлежит: Confluent Surgical Inc, COVIDIEN LP

Crosslinked polymers, methods for their preparation and use, are described in which the crosslinked polymers are formed from at least two polymer precursors, one of which is designed, upon degradation of the crosslinked polymer, to release the second polymer precursor in its original, unmodified chemical form.

Подробнее
05-09-2013 дата публикации

Novel Intermediate for Preparing Tapentadol or Analogues Thereof

Номер: US20130231478A1
Принадлежит:

The invention discloses a novel intermediate for preparing tapentadol and analogues thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogues thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production. 2. The compound according to claim 1 , wherein Ris selected from Cl claim 1 , methyl claim 1 , OH claim 1 , NHor methoxy.3. The compound according to claim 1 , characterized in that Y is selected from OR claim 1 , wherein Ris selected from methyl claim 1 , ethyl claim 1 , n-propyl or isopropyl.4. The compound according to claim 1 , characterized in that Y is selected from NRR claim 1 , wherein R claim 1 , Rand N form substituted or unsubstituted saturated nitrogen-containing heteorcyclyl containing oxygen or not jointly.5. The compound according to claim 4 , wherein R claim 4 , Rand N form tetrahydropyrrole ring claim 4 , piperidine ring claim 4 , 4-methylpiperidine ring claim 4 , morpholine ring claim 4 , methylpiperazine ring or 4-hydroxypiperidine jointly.6. The compound according to claim 1 , selected from the following compounds:valeryl 2-methyl-3-(3-methoxyphenyl)chloride;methyl 2-methyl-3-(3-methoxyphenyl)sulfovalerate;methyl 2-methyl-3-(3-hydroxyphenyl) ulfovalerate;2-methyl-3-(3-hydroxyphenyl)sulfovaleramide;N,N-dimethyl-2-methyl-3-(3-methoxyphenyl)sulfovaleramide;N,N-dimethyl-2-methyl-3-(3-hydroxyphenyl)sulfovaleramide;N,N-diethyl-2-methyl-3-(3-methoxyphenyl)valeramide;3-(3-methoxyphenyl)-2-methyl-1-(piperidin-1-yl)pentan-1-one;3-(3-methoxyphenyl)-2-methyl-1-(4-methylpiperidin-1-yl)pentan-1-one;3-(3-methoxyphenyl)-2-methyl-1-(morpholin-1-yl)pentan- ...

Подробнее
12-09-2013 дата публикации

Process for Preparing Esteramide Compounds

Номер: US20130237722A1
Принадлежит: Rhodia Operations

The present invention relates to a method for preparing esteramide compounds. More particularly, the invention relates to a method for preparing esteramide compounds by reaction between a diester and an amine, in the presence of a basic compound, wherein 1. A method for preparing an esteramide compound of the following formula (I):{'br': None, 'sup': 1', '2', '3, 'ROOC-A-CONRR\u2003\u2003(I)'}comprising a reaction step between: {'br': None, 'sup': 1', '1, 'ROOC-A-COOR\u2003\u2003(II)'}, 'a diester compound of the following formula (II) {'br': None, 'sup': 2', '3, 'HNRR\u2003\u2003(III)'}, 'and an amine of the following formula (III)in the presence of a basic compound, A is a covalent bond or a linear or branched divalent alkylene group comprising a number of carbon atoms ranging from 1 to 12,', {'sup': '1', 'Ris an optionally substituted hydrocarbon group, comprising from 1 to 36 carbon atoms,'}, {'sup': 2', '3, 'Rand R, either identical or different, are groups selected from hydrogen and optionally substituted hydrocarbon groups, comprising from 1 to 36 carbon atoms,'}, {'sup': 2', '3, 'Rand Rmay form together a ring comprising the nitrogen atom to which they are bound, said ring being substituted, if necessary, and/or comprising an additional heteroatom, and'}, {'sup': 2', '3, 'Rand Rnot being simultaneously hydrogen atoms,'}], 'wherein the amine (III) is solubilized in an organic solvent, or in the diester compound (II),', 'when the amine (III) is solubilized in an organic solvent, the diester compound (II) is added onto the reaction mixture comprising the amine (III) and the basic compound,', 'when the amine (III) is solubilized in the diester compound (II), the basic compound is added onto the reaction mixture comprising the amine (III) and the diester compound (II),', 'the reaction is conducted at a temperature greater than or equal to 30° C.,', 'the amine (III) is present in molar excess ranging from 0.01 to 50%, based on the diester compound (II)., ' ...

Подробнее
19-09-2013 дата публикации

Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst

Номер: US20130245257A1
Принадлежит: KYOTO UNIVERSITY, Sumitomo Chemical Co Ltd

The invention provides a compound having a heterocyclic skeleton of formula (I): wherein the substituents are as defined in the specification, as well as a tautomer thereof or a salt thereof. The invention also provides asymmetric synthesis methods involving the use of such a compound, tautomer thereof, or salt thereof, as a catalyst.

Подробнее
19-09-2013 дата публикации

Synthesis of Tripodal Catechol Derivatives Having an Adamantyl Basic Framework for Functionalizing Surfaces

Номер: US20130245269A1
Принадлежит: Justus Liebig Universitaet Giessen

The present invention describes tripodal catechol derivatives with an adamantyl basic framework for the functionalisation of surfaces, methods for their production and use. The remaining fourth bridgehead position is easily suitable to be further functionalised via so-called click reactions, by way of example with biomolecules, dyes, radiomarkers, polyethylene glycol or active agents. The compounds according to the present invention have the general formula X-Ad[(CH 2 ) n —YZ] 3 , wherein A stands for the adamantyl skeleton, X stands for a group —(CH 2 ) p —R 5 , wherein p=0 to 10 and R 5 is selected from —H, —NH 2 , —NO 2 , —OH, —SH, —O—NH 2 , —NH—NH 2 , —N═C═S—, —N═C═O—, —CH═CH 2 , —C≡CH, —COOH, —(C═O)H, —(C═O)R 6 Y stands for —CH 2 —, —CH═CH—, —O—, —S—, —S—S—, —NH—, —O—NH—, —NH—O—, —HC═N—O—, —O—N═CH—, —NR 1 —, -aryl-, -heteroaryl-, —(C═O)—, —O—(C═O)—, —(C═O)—O—, —NH—(C═O)—, —(C═O)—NH—, —NR 1 —(C═O)—, —(C═O)—NR 1 —, —NH—(C═O)—NH—, —NH—(C═S)—NH—, R 1 stands for an alkyl group, R 6 for an alkyl, alkenyl, alkynyl, aryl or heteroaryl group, and Z stands for a catechol derivative. The production of the compounds occurs by reacting a compound X-Ad[(CH 2 ) n —Y′] 3 with a reagent Y″Z to the corresponding compound X-Ad[(CH 2 ) n —YZ] 3 and subsequently purifying the reaction product. Y′ and Y″ are hereby precursors of Y. The compounds according to formula (I) according to the present invention are suitable to be used in a method to functionalise surfaces. The X group of the compounds according to the present invention is suitable to be optionally coupled to an effector, for example, by means of click chemistry.

Подробнее
19-09-2013 дата публикации

Synthesis of Trivalent Flexible Frameworks with Ligands Comprising Catechol Units for Functionalizing Surfaces

Номер: US20130245270A1
Принадлежит: JUSTUS-LIEBIG-UNIVERSITAT GIESSEN

The present invention describes tripodal catechol derivatives with a flexible basic framework for the functionalisation of surfaces, and methods for their production and use. The central atom of the flexible framework is hereby a tertiary aliphatic carbon atom. The remaining fourth bridgehead position is easily suitable to be further functionalised via so-called click reactions, e.g. with biomolecules, dyes, radiomarkers, polyethylene glycol or active agents. 2. The compound according to claim 1 , wherein Y is a bond claim 1 , —CH— claim 1 , —NH—(C═O)— claim 1 , —(C═O)—NH— claim 1 , or —NR—.3. The compound according to claim 1 , wherein n is an integer between 0 and 3.4. The compound according to claim 1 , m is an integer between 0 and 3.7. The compound according to claim 1 , wherein X is —(CH)—R claim 1 , and p is an integer between 0 and 3.8. The compound according to claim 1 , wherein{'sub': 2', 'p, 'sup': '5', 'X is —(CH)—R,'}{'sup': 5', '6', '6', '7', '6, 'sub': 2', '2', '2', '2, 'Ris —H, —OH, —NH, —NO, —NH—NH, —NHR, —NRR, —O—NH, —NH—(C═O)—C≡CH, —C≡CH, —N═C═S, —N═C═O, —COOH, —(C═O)H, or —(C═O)R, and'}p is an integer between 0 and 3.10. The method according to claim 9 , wherein X is a hydrogen atom.11. The method according to claim 9 , wherein{'sub': 2', 'p, 'sup': '5', 'X is —(CH)—R,'}{'sup': 5', '6', '6', '7', '6, 'sub': 2', '2', '2', '2, 'Ris —OH, —NH, —NO, —NH—NH, —NHR, —NRR, —O—NH, —NH—(C═O)—C≡CH, —C≡CH, —N═C═S, —N═C═O, —COOH, —(C═O)H, or —(C═O)R, and'}p is an integer between 0 and 3.12. The method according to claim 11 , wherein Ris protected by a protective group (Pg) prior to reacting the compound with the reagent Y″Z claim 11 , so that the compound Pg-X—C[(CH)—Y′]is reacted with the reagent Y″Z to produce a corresponding compound Pg-X—C[(CH)—YZ].13. (canceled)14. (canceled)15. (canceled) The present invention describes tripodal catechol derivatives with a flexible basic framework for the functionalisation of surfaces, and methods for their production ...

Подробнее
19-09-2013 дата публикации

Process For Making Amides

Номер: US20130245297A1
Принадлежит: BASF SE

Provided are processes for making an amide of a carboxylic acid by reacting an amine of the formula (I) 2. The process of claim 1 , wherein measures (a) and (b) are carried out without the use of any organic solvent.3. The process of claim 1 , wherein the reaction in measure (a) is carried out at a temperature in the range of from 130 to 230° C.4. The process of claim 1 , wherein the carboxylic acid comprises lactic acid.5. The process of claim 1 , wherein the amine according to formula (I) comprises methylamine claim 1 , dimethylamine claim 1 , ethylamine claim 1 , diethylamine claim 1 , n-propylamine claim 1 , isopropylamine claim 1 , diisopropylamine claim 1 , n-butylamine claim 1 , iso-butylamine claim 1 , tert-butylamine claim 1 , methyl n-propylamine claim 1 , n-methyl-n-ethyl amine claim 1 , or methyl iso-propylamine.6. The process of claim 1 , wherein the single reactor is connected to a fractionation column and a condenser.7. The process of claim 1 , wherein the single reactor is connected to a combination of two fractionation columns and two condensers.8. The process of claim 1 , wherein the step for re-introducing the unreacted amine according to formula (I) into the reaction mixture comprises using liquid jet nozzles.9. The process of claim 1 , wherein the carboxylic acid comprises caprylic acid claim 1 , capric acid claim 1 , or lauric acid and the amine comprises dimethylamine or diethylamine.10. The process of claim 1 , wherein the molar ratio of amine according to formula (I) to carboxylic acid is in the range of from 1.2:1 to 1:1 This application claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Application No. 61/612,452, filed Mar. 19, 2012, which is incorporated herein by reference in its entirety.The present invention is directed towards a process for making an amide of a carboxylic acid by reacting an amine of the formula (I)H—NRR  (I)Rand Rbeing defined as being the same or different,Rbeing selected from C-C-alkyl,Rbeing selected ...

Подробнее
19-09-2013 дата публикации

METHOD FOR PRODUCING SANSHOOL

Номер: US20130245303A1
Автор: Aoki Katsuyuki
Принадлежит: TSUMURA & CO.

Provided are a method for producing a sanshool, which method has a short process and exhibits high stereoselectivity, as well as an iron carbonyl complex compound that is an intermediate useful for the production method. 4. The method for producing a sanshool according to claim 3 , wherein the deprotecting agent is one selected from the group consisting of cerium (IV) compounds claim 3 , trimethylamine N-oxide claim 3 , pyridine N-oxide claim 3 , iron (III) chloride claim 3 , copper (II) chloride claim 3 , dichlorodicyano benzoquinone claim 3 , and hydrogen peroxide. The present invention relates to a method for producing a sanshool and to a diene iron complex compound that is an intermediate useful for the production method. In particular, the invention relates to a method for producing a sanshool, which can produce a sanshool in a short process and with high stereoselectivity, as well as to a novel diene iron complex compound that is an intermediate useful for the production method.Sanshools are a main ingredient of a crude drug, “Zanthoxylum Fruit”. In recent years, HαS (hydroxy-α-sanshool) has been reported to have effects such as stimulations of TRPV1 and TRPA1 and is now in the spotlight of the medicinal chemical field.Sanshools including HαS have an unstable structure due to a triene moiety. Therefore, it has been difficult to constantly produce and supply sanshool as a pure substance. Conventionally, sanshools have been isolated and purified from an extract of sanshoo as a raw material by silica gel and ODS column chromatography.Total syntheses of HαS and HβS (hydroxy-β-sanshool) have not been reported in the past, but a total synthesis of α-sanshool as an analogue thereof has been reported (see Non-Patent Documents 1 and 2). Methods described in the Non-Patent Documents 1 and 2 are both those for forming a triene moiety by a Wittig reaction.However, the methods described in Non-Patent Documents 1 and 2 have showed low yield and low E/Z selectivity and thus ...

Подробнее
03-10-2013 дата публикации

PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES

Номер: US20130261178A1
Принадлежит:

A compound of formula I-0, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: 2. The compound as claimed in wherein Ris selected from unsubstituted and substituted Ccycloalkyl claim 1 , Ccycloalkyl-Calkyl claim 1 , Calkyl claim 1 , Caryl-Calkyl claim 1 , Calkoxy-Caryl-Calkyl.3. The compound as claimed in wherein Xis selected from CO claim 1 , CS claim 1 , SOand a single bond.4. The compound as claimed in wherein Rand Rare selected from ROZO as hereinbefore defined claim 1 , m- claim 1 ,p-(OCH)or o- claim 1 , m- or p-OH claim 1 , F claim 1 , Cl claim 1 , Br claim 1 , NH claim 1 , R claim 1 , OR claim 1 , or CFor a combination thereof.12. A process for the preparation of a compound of formula I-0 or subformulae as defined in .14. A composition comprising a therapeutically effective amount of a compound of formula I-0 or subformulae or its pharmaceutically acceptable salt and physiologically hydrolysable derivative as defined in in association with one or more pharmaceutical carriers or diluents.15. The use of a compound of formula I-0 or subformulae or pharmaceutically acceptable salt or composition as defined in in the prevention or treatment of a condition selected from ischaemic heart disease claim 1 , hypertension and heart failure claim 1 , more preferably with concomitant respiratory disease claim 1 , in particular asthma or COPD.16. A method of treating a condition selected from ischaemic heart disease (also known as myocardial infarction or angina) claim 1 , hypertension and heart failure claim 1 , restenosis and cardiomyopathy claim 1 , more preferably with concomitant respiratory disease claim 1 , in particular asthma or COPD claim 1 , said method comprising administering to a subject in need thereof claim 1 , a compound of formula I-0 or subformulae or pharmaceutically acceptable salt or composition thereof as defined in in an amount sufficient to treat the condition.17. A method of ...

Подробнее
03-10-2013 дата публикации

GENETICALLY ENCODED INITIATOR FOR POLYMER GROWTH FROM PROTEINS

Номер: US20130261259A1
Принадлежит: FRANKLIN AND MARSHALL COLLEGE

This invention pertains to methods for producing homogeneous recombinant proteins that contain polymer initiators at defined sites. The unnatural amino acid, 4-(2′-bromoisobutyramido)phenylalanine of formula 1, was designed and synthesized as a molecule comprising a functional group further comprising an initiator for an atom-transfer radical polymerization (‘ATRP”) that additionally would provide a stable linkage between the protein and growing polymer. We evolved a (Mj) tyrosyl-tRNA synthetase/tRNApair to genetically encode this unnatural amino acid in response to an amber codon. To demonstrate the utility of this functional amino acid, we produced Green Fluorescent Protein with the unnatural amino acid initiator of formula 1 site-specifically incorporated on its surface (GFP-1). Purified GFP-1 was then used as an initiator under standard ATRP conditions with oligo(ethylene oxide)monomethyl ether methacrylate, efficiently producing a polymer-GFP bioconjugate wherein the polymer is connected at a specifically selected site on GFP. 2. The compound of claim 1 , as described by formula 6 claim 1 , wherein R1 and R2 are independently H claim 1 , methyl claim 1 , or phenyl; X is F claim 1 , Cl claim 1 , Br claim 1 , I; or N; A is O claim 1 , S claim 1 , or NR claim 1 , wherein R is H claim 1 , methyl claim 1 , or phenyl; n is 1; or a salt thereof.6. The compound of claim 1 , wherein R1 and R2 are independently H claim 1 , methyl claim 1 , or phenyl; X is F claim 1 , Cl claim 1 , Br claim 1 , I claim 1 , or N; A is O claim 1 , S claim 1 , or NR claim 1 , wherein R is H claim 1 , methyl claim 1 , or phenyl; n is 0; or a salt thereof.14. The method of claim 13 , wherein R1 and R2 are independently H claim 13 , methyl claim 13 , or phenyl; X is F claim 13 , Cl claim 13 , Br claim 13 , I claim 13 , or N; Y is F claim 13 , Cl claim 13 , Br claim 13 , I claim 13 , or trifluoroacetate; A is O claim 13 , S claim 13 , or NR claim 13 , wherein R is H claim 13 , methyl claim 13 , ...

Подробнее
03-10-2013 дата публикации

SYNTHESIS OF ALISKIREN

Номер: US20130261324A1
Принадлежит:

The present invention provides novel process for the preparation of renin inhibitor Aliskiren or its derivatives, and its pharmaceutically acceptable salts. The present invention also provides novel intermediates used in the preparation of Aliskiren. 3. The process according to claim 1 , wherein the reduction of the azide group of the compound of Formula-IV is carried out by using a palladium catalyst.4. The process according to claim 1 , wherein the reduction of the azide group of the compound of Formula-IV is carried out in the presence of an alcoholic solvent.5. The process according to claim 4 , wherein the alcoholic solvent used in the reduction of the azide compound of Formula-IV is selected from the group consisting of ethanol claim 4 , methanol claim 4 , and isopropanol.7. The process according to claim 6 , wherein the compound of Formula-V is purified by fractional distillation.9. Use of a compound of Formula-III as a starting compound in the preparation of Aliskiren or a pharmaceutically acceptable salts thereof. The present invention relates to novel process for the preparation of renin inhibitor Aliskiren or its derivatives, and its pharmaceutically acceptable salts.Aliskiren, (2S,4S,5S,7S)—N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide having the Formula-I, a new antihypertensive has been developed which interferes with the renin-angiotensin system at the beginning of angiotensin II biosynthesis.Aliskiren is marketed by Novartis as TEKTURNA® in the form of its hemifumarate salt in a once-daily formulation. More recently Aliskiren is also formulated as combination with other API.U.S. Pat. No. 5,559,111 discloses Aliskiren and related compounds along with the different approaches for the synthesis of Aliskiren.Further U.S. Pat. No. 7,132,569, U.S. Pat. No. 7,009,078, U.S. Pat. No. 6,730,798 and U.S. Pat. No. 6,800,769 claims novel intermediates used in the preparation of Aliskiren and ...

Подробнее
03-10-2013 дата публикации

METHOD FOR PRODUCING SANSHOOL

Номер: US20130261327A1
Автор: Aoki Katsuyuki
Принадлежит: TSUMURA & CO.

Provided are a method for producing a sanshool, which can produce a sanshool in a short process and with high stereoselectivity, as well as a novel diene iron complex compound that is a stable intermediate useful for the production method. The diene iron complex compound is represented by the following general formula (I): 3. The method for producing a sanshool according to claim 2 , wherein the deprotecting agent is selected from the group consisting of cerium (IV) compounds claim 2 , trimethylamine N-oxide claim 2 , pyridine N-oxide claim 2 , iron (III) chloride claim 2 , copper (II) chloride claim 2 , dichlorodicyano benzoquinone claim 2 , and hydrogen peroxide.5. The method for producing a sanshool according to claim 4 , wherein lithium hydroxide is used as a base in the step of reacting the aldehyde compound with (E)-N-isobutyl-diethylphosphonocrotonic acid amide claim 4 , (E)-N-(2-methyl-2-hydroxy-propyl)-diethylphosphonocrotonic acid amide claim 4 , or (E)-N-(2 claim 4 ,2-dimethyl-propyl)-diethylphosphonocrotonic acid amide.7. The method for producing a sanshool according to claim 6 , wherein lithium hydroxide is used as a base in the step of reacting the aldehyde compound with triethyl 4-phosphonocrotonate.9. The method for producing a sanshool according to claim 8 , wherein lithium hydroxide is used as a base in the step of reacting the aldehyde compound with triethyl 4-phosphonocrotonate. The present invention relates to a method for producing a sanshool and to a diene iron complex compound that is an intermediate useful for the production method. In particular, the invention relates to a method for producing a sanshool, which can produce a sanshool in a short process and with high stereoselectivity, as well as to a novel diene iron complex compound that is an intermediate useful for the production method.Sanshools are a main ingredient of a crude drug, “Zanthoxylum Fruit”. In recent years, gamma-sanshool has been reported to have effects such as the ...

Подробнее
03-10-2013 дата публикации

Process for the Preparation of Iosimenol

Номер: US20130261338A1
Принадлежит: Mallinckrodt LLC

A process for the preparation of iosimenol comprising reacting 5,5′-[(1,3-dioxo-1,3-propanediyl)diimino]bis[N-(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide] (C-VI) with a 3-halo-1,2-propanediol in an aqueous solvent. A process for the preparation of C-VI comprising reacting 3,3′4(1,3-dioxo-1,3-propanediyl)diimino]bis[5-(aminocarbonyl)-2,4,6-triiodobenzoyl chloride] (C-V) with 3-amino-1,2-propanediol in the presence of an inorganic base and a suitable non-aqueous polar solvent. A process for the preparation of C-V comprising reacting 3-amino-5-(aminocarbonyl)-2,4,6-triiodobenzoyl chloride (C-IV) with malonyl dichloride in a solvent comprising a suitable ester solvent, a suitable nitrile solvent or mixtures thereof. 121-. (canceled)23. The process of wherein the solvent further comprises a suitable ethereal solvent.24. The process of wherein the solvent optionally further comprises a suitable ethereal solvent claim 22 , and the solvent is selected from acetonitrile claim 22 , ethyl acetate claim 22 , a mixture of acetonitrile and tetrahydrofuran claim 22 , a mixture of ethyl acetate and tetrahydrofuran claim 22 , a mixture of acetonitrile and 1 claim 22 ,2-dimethoxyethane claim 22 , a mixture of ethyl acetate and 1 claim 22 ,2-dimethoxyethane claim 22 , or a mixture of acetonitrile and ethyl acetate.25. The process of wherein the solvent is selected from acetonitrile claim 24 , ethyl acetate claim 24 , a mixture of acetonitrile and tetrahydrofuran claim 24 , a mixture of ethyl acetate and tetrahydrofuran claim 24 , or a mixture of acetonitrile and ethyl acetate.26. The process of wherein the solvent comprises acetonitrile or a mixture of acetonitrile and tetrahydrofuran.27. The process of wherein the solvent is a mixture of acetonitrile and tetrahydrofuran wherein the weight ratio of acetonitrile:tetrahydrofuran is about 1:9 to about 49:1.28. The process of wherein the weight ratio of acetonitrile:tetrahydrofuran is about 1:1 to about 49:1.29. The ...

Подробнее
10-10-2013 дата публикации

Aromatic ketone synthesis with amide reagents and related reactions

Номер: US20130267712A1
Принадлежит: Northern Illinois University

A method of preparing an aryl carbonyl or aryl thiocarbonyl compound, comprises reacting an N-(nitroaryl)-amide or N-(nitroaryl)-thioamide with an aromatic ring, with a superacid catalyst, to produce the aryl carbonyl or aryl thiocarbonyl compound. The superacid is present in an amount of at most 8 equivalents in proportion to the N-(nitroaryl)-amide or N-(nitroaryl)-thioamide. A method of preparing aryl amide or aryl thioamide, comprises reacting an N-(nitroaryl)-carbamide or N-(nitroaryl)-thiocarbamide with an aromatic ring, with a superacid catalyst, to produce the aryl amide or aryl thioamide.

Подробнее
10-10-2013 дата публикации

BIDENTATE CHIRAL LIGANDS FOR USE IN CATALYTIC ASYMMETRIC ADDITION REACTIONS

Номер: US20130267714A1
Принадлежит:

Compounds of the formula (I) in the form of a mixture of predominantly one diastereomer or in the form of pure diastereomers, 1. Compounds of the formula (I) in the form of a mixture of predominantly one diastereomer or in the form of pure diastereomers ,{'br': None, 'sub': 1', '0', '1, 'Z-Q-P*RR\u2003\u2003(I),'}wherein:{'sub': 1', '2, 'claim-text': {'sub': 1', '6', '1', '6', '1', '4', '2', '6', '5', '3', '1', '12', '3, 'wherein R is a hydrocarbon radical or O-atom(s)-containing heterohydrocarbon radical having 1 to 18 carbon atoms and optionally substituted by C-C-alkyl, trifluoromethyl, C-C-alkoxy, trifluoromethoxy, (C-C-alkyl)amino, (CH)Si, (C-C-alkyl)Si or halogen;'}, 'Zis a C-bonded, secondary phosphine group of the formula —P(R),'} [{'sub': 1', '0', '1, '(i) an optionally substituted achiral aromatic group, wherein the achiral aromatic group is bonded directly to Zthrough a carbon atom of the achiral aromatic group and bonded directly to P*RRthrough a carbon atom of the achiral aromatic group, and'}, {'sub': 1', '4, '(ii) an optionally substituted C-C-alkylene group;'}], 'Q is selected from the group consisting ofP* is a chiral phosphorus atom;{'sub': '0', 'Ris methyl; and'}{'sub': '1', 'Ris a C-bonded optically enriched or optically pure chiral, mono- or polycyclic, nonaromatic hydrocarbon ring.'}23-. (canceled)4. The compounds according to claim 1 , wherein the secondary phosphine Zis selected from the group consisting of: —P(C-C-alkyl) claim 1 , —P(C-C-cycloalkyl) claim 1 , —P(o-furyl) claim 1 , —P(CH) claim 1 , —P[2-(C-C-alkyl)CH] claim 1 , —P[3-(C-C-alkyl)CH] claim 1 , —P[4-(C-C-alkyl)CH] claim 1 , —P[2-(C-C-alkoxy)CH] claim 1 , —P[3-(C-C-alkoxy)CH] claim 1 , —P[4-(C-C-alkoxy)CH] claim 1 , —P[2-(trifluoromethyl)CH] claim 1 , —P[3-(trifluoromethyl)CH] claim 1 , —P[4-(trifluoromethyl)CH] claim 1 , —P[3 claim 1 ,5-bis(trifluoromethyl)CH] claim 1 , —P[3 claim 1 ,5-bis(C-C-alkyl)CH] claim 1 , —P[3 claim 1 ,5-bis(C-C-alkoxy)CH]and —P[3 claim 1 ,5-bis(C-C-alkyl ...

Подробнее
10-10-2013 дата публикации

METHOD FOR PREPARING 2-AMINO-N-(2,2,2-TRIFLUOROETHYL) ACETAMIDE

Номер: US20130267729A1
Автор: Bruening Joerg
Принадлежит: E.I. Du Pont De Nemours and Company

Disclosed are methods for preparing compounds of Formula 1 and 1A. The first method utilizes a benzyl carbamate amine protecting group and an intermediate of Formula 4. The second method utilizes a tert-butyl carbamate amine protecting group and an intermediate of Formula 7. The third method utilizes a dibenzyl amine protecting group. Also disclosed is a compound, phenylmethyl N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]carbamate (a compound of Formula 4). Further disclosed is a method for preparing a compound of Formula 14 from a compound of Formula 15 and a compound of Formula 1 or 1A. 2. The method of step (A) wherein the compounds of Formulae 2 and 3 and the coupling reagent are contacted in the presence of a base and a water immiscible solvent.3. The method of wherein the base is derived from the coupling reagent and the coupling reagent is N claim 2 ,N′-carbonyldiimidazole.4. The method of step (B) wherein the compound of Formulae 4 and hydrogen are contacted in the presence of a hydrogenolysis catalyst and a water immiscible solvent.5. The method of wherein the hydrogenolysis catalyst is palladium on carbon.6. The method of step (C) wherein the compound of Formula 1 is contacted with an acid of Formula 5 in the presence of a water immiscible solvent.7. The method of wherein the acid of Formula 5 comprises hydrogen chloride.8. (canceled)9. A compound which is phenylmethyl N-[2-oxo-2-[(2 claim 6 ,2 claim 6 ,2-trifluoroethyl)amino]-ethyl]carbamate.11. The method of step (A1) wherein the compounds of Formulae 8 and 3 and the coupling reagent are contacted in the presence of a base and a water immiscible solvent.12. The method of wherein the base is derived from the coupling reagent and the coupling reagent is N claim 11 ,N′-carbonyldiimidazole.13. The method of step (B1) wherein the compounds of Formulae 7 and 5 are contacted in the presence of a water immiscible solvent.14. The method of wherein the acid of Formula 5 comprises hydrogen chloride.15. (canceled) ...

Подробнее
10-10-2013 дата публикации

AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF

Номер: US20130267738A1
Принадлежит: LES LABORATORIES SERVIER

The present invention relates to the intermediate compounds for preparation of agomelatine, as well as the preparation methods thereof. The intermediate of the present invention for preparation of agomelatine is compound A as shown in the following formula. Also provided are two novel intermediate compounds. When we use these new intermediate compounds to prepare agomelatine, it is simple to manipulate, well-controlled and with high purity, without complicated operations such as rectification and column chromatography separation, and suitable for industrial production. Meanwhile, the preparation methods of the two new intermediates themselves is simple and high yield, only using the most commonly-used 7-methoxy-tetralone as original starting material and undergoing one step of reaction to obtain the intermediates, followed by one more step of converting the intermediate compounds to desired product agomelatine. Said reaction processes are greatly simplified, with the reaction yield being improved and the difficulty in purification of previous method being overcome, as compare with the previous technique for preparation of agomelatine. Typically, the yield of the present invention is over 70%. 116-. (canceled)20. The method according to claim 19 , wherein the metal catalyst is Raney-Ni claim 19 , the amount of which is 0.1-0.3 times the amount of the compound C by weight.21. The method according to claim 19 , wherein the amount of the acetic anhydride is 1-1.3 times the molar amount of the compound C.23. The method according to claim 22 , wherein the dehydrogenating agent used in the aromatization is dichloro-dicyanobenzoquinone.24. The method according to claim 22 , wherein the amount of dehydrogenating agent is 1-3 times the molar amount of the compound A.25. The method according to claim 22 , wherein the solvent used in the reaction is a mixture of toluene and glacial acetic acid claim 22 , a mixture of acetonitrile and glacial acetic acid claim 22 , or glacial ...

Подробнее
17-10-2013 дата публикации

Processes For Preparing A Polymeric Compound

Номер: US20130274502A1
Принадлежит: POLYMEDIX, INC.

The present invention provides methods for preparing a polymeric compound of Formula I: The present invention was supported, in part, by funds from the U.S. Government (SBIR Phase 1 grant No. 1R43HL090113-01) and the U.S. Government may therefore have certain rights in the invention.The present invention is directed, in part, to methods for preparing a polymeric salicylamide compound and/or pharmaceutically acceptable salts thereof, as well as to useful intermediates for the preparation of the polymeric salicylamide compound and/or pharmaceutically acceptable salts thereof.The polymeric salicylamide compound of Formula I:and/or pharmaceutically acceptable salts thereof are useful, for example, as pharmaceutical agents for inhibiting angiogenesis (see, WO 2005/123660). Given the importance of the compound of Formula I and/or pharmaceutically acceptable salts thereof as pharmaceutical agents, effective synthetic methods for preparing the compound and its pharmaceutically acceptable salts is of great import. This invention is directed to this, as well as other, important ends.The present invention provides, in part, methods for preparing a compound of Formula I:or pharmaceutically acceptable salt thereof, comprising:a) removing the Cbz groups from a compound of Formula II:or pharmaceutically acceptable salt thereof, under a hydrogenation/hydrogenolysis condition to form the compound of Formula I, or pharmaceutically acceptable salt thereof; andb) optionally isolating the compound of Formula I, or pharmaceutically acceptable salt thereof.In some embodiments, the hydrogenation/hydrogenolysis condition comprises using a metal catalyst. In some embodiments, the metal catalyst is Pd/C. In some embodiments, the reaction yield in step a) is greater than about 85%.In some embodiments, the methods further comprise:c) removing the Boc group from a compound of Formula III:or pharmaceutically acceptable salt thereof, in the presence of an acid to form the compound of Formula II, ...

Подробнее
24-10-2013 дата публикации

Novel ruthenium complexes and their uses in processes for formation and/or hydrogenation of esters, amides and derivatives thereof

Номер: US20130281664A1
Принадлежит: Yeda Research and Development Co Ltd

The present invention relates to novel Ruthenium catalysts and related borohydride complexes, and the use of such catalysts, inter alia, for (1) hydrogenation of amides (including polyamides) to alcohols and amines; (2) preparing amides from alcohols with amines (including the preparation of polyamides (e.g., polypeptides) by reacting dialcohols and diamines and/or by polymerization of amino alcohols); (3) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones) or cyclic di-esters (di-lactones) or polyesters); (4) hydrogenation of organic carbonates (including polycarbonates) to alcohols and hydrogenation of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (5) dehydrogenative coupling of alcohols to esters; (6) hydrogenation of secondary alcohols to ketones; (7) amidation of esters (i.e., synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water to form carboxylic acids; and (10) dehydrogenation of beta-amino alcohols to form pyrazines. The present invention further relates to the novel uses of certain pyridine Ruthenium catalysts.

Подробнее
31-10-2013 дата публикации

PROCESS FOR THE PREPARATION OF PRAZIQUANTEL

Номер: US20130289275A1
Принадлежит:

The present disclosure describes a novel, cost-effective process for preparation of a 4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino-[2,1-a]isoquinoline derivatives. Specifically, it discloses a process for the preparation of the anthelmintic drug praziquantel through the use of a novel intermediate, 2-[(2,2-dimethoxyethyl)benzyl amino]-N-phenethylacetamide. This present disclosure also describes a novel crystalline form of 4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinoline. 1. A process for the preparation of 2-[(2 ,2-dimethoxyethyl)amino]-N-(2-phenylethyl)acetamide , which comprises:a) condensation of β-phenylethylamine with chloroacetyl chloride in the presence of a solvent and a base to obtain 2-chloro-N-phenethylacetamide;b) condensation of benzylamine with chloroacetaldehyde dimethylacetal in the presence of water and a base to obtain N-benzyl-2,2-dimethoxyethanamine;c) condensation of 2-chloro-N-phenethylacetamide prepared in step a) with N-benzyl-2,2-dimethoxyethanamine of formula VI prepared in step b) in the presence of water and a base to obtain 2-[(2,2-dimethoxyethyl)benzylamino]-N-phenethylacetamide; andd) reduction of 2-[(2,2-dimethoxyethyl)benzylamino]-N-phenethylacetamide using a reducing agent and a solvent in the presence of hydrogen to obtain 2-[(2,2-dimethoxyethyl)amino]-N-(2-phenylethyl)acetamide.2. A process according to claim 1 , wherein the solvent in step a) is toluene and the base in step a) is sodium bicarbonate.3. A process according to claim 1 , wherein the solvent in step b) and step c) is water and the base in step b) and step c) is sodium hydroxide.4. A process according to claim 1 , wherein the solvent in step d) is selected from the group consisting of methanol claim 1 , ethanol claim 1 , and isopropanol claim 1 , and the reducing agent in step d) is selected from the group consisting of Raney nickel claim 1 , platinum claim 1 , and palladium on carbon.5. A process for preparation of praziquantel which comprises:{'claim-ref': ...

Подробнее
31-10-2013 дата публикации

PROCESS FOR THE SYNTHESIS OF AGOMELATINE

Номер: US20130289307A1
Принадлежит: LES LABORATOIRES SERVIER

Process for the industrial synthesis of the compound of formula (I) 120-. (canceled)23. The process according to claim 21 , wherein the compound of formula (VII) is subjected to reduction by hydrogen in the presence of Raney nickel in a medium comprising acetic anhydride in a polar protic medium to yield the compound of formula (I) claim 21 , which is isolated in the form of a solid.24. The process according to claim 21 , wherein the group Xa represents —S—C(S)—OCH.25. The process according claim 21 , to claim 21 , wherein the free radical reactions are initiated by thermal means at a temperature of from 50 to 140° C.26. The process according to claim 21 , wherein cyclisation of compound of formula (IV) is carried out at a temperature of from 130 to 135° C.27. The process according to claim 21 , wherein the step of addition of the compound of formula (II) to the compound of formula (III) and that of cyclisation of the compound of formula (IV) are initiated in the presence of dilauroyl peroxide.28. The process according to claim 21 , wherein the step of addition of the compound of formula (II) to the compound of formula (III) is carried out in chlorobenzene.29. The process according t claim 21 , wherein the step of cyclisation of the adduct of formula (IV) to form the compound of formula (V) is carried out in ethyl acetate.30. The process according to claim 21 , wherein the conversion of the compound of formula (V) into the compound of formula (VI) is carried out in the presence of aluminium isopropoxide.31. The process according to wherein the conversion of the compound of formula (V) into the compound of formula (VI) is carried out in isopropanol.32. The process according to claim 21 , a catalytic amount of p-toluenesulphonic acid is added to the mixture at the end of conversion of the compound of formula (V) into the compound of formula (VI).33. The process according to claim 21 , wherein the aromatisation of the compound of formula (VI) is carried out in the ...

Подробнее
31-10-2013 дата публикации

PROCESS FOR THE SYNTHESIS OF AGOMELATINE

Номер: US20130289308A1
Принадлежит: LES LABORATOIRES SERVIER

Process for the industrial synthesis of the compound of formula (I) 126-. (canceled)29. The process according to claim 27 , wherein the group Xa represents —S—C(S)—OCH.30. The process according to claim 27 , wherein the free radical reactions are initiated by thermal means at a temperature of from 50 to 140° C.31. The process according to claim 27 , wherein the step of addition of the compound of formula (II) to the compound of formula (III) is initiated in the presence of dilauroyl peroxide.32. The process according to claim 27 , wherein the reaction of cyclisation of the adduct of formula (IV) is carried out in the presence of dilauroyl peroxide optionally with dibenzoyl peroxide.33. The process according to claim 27 , wherein the step of addition of the compound of formula (II) to the compound of formula (III) and the step of cyclisation of the adduct of formula (IV) are carried out in ethyl acetate.36. The process according to claim 35 , wherein X represents Cl.37. The process according to claim 35 , wherein X represents Br.38. The process according to claim 27 , wherein the reaction deprotecting the amine function of the compound of formula (V) claim 27 , when the amine function is protected by a phthalimide group claim 27 , is carried out in the presence of sodium borohydride or a hydrazine-type agent.39. The process according to claim 34 , wherein the step of aromatisation of the compound of formula (VII) is carried out using a benzoquinone.40. The process according to claim 39 , wherein the benzoquinone is 2 claim 39 ,3-dichloro-5 claim 39 ,6-dicyano-1 claim 39 ,4-benzoquinone (DDQ).41. The process according to claim 35 , wherein the aromatisation of the compound of formula (VI) is carried out in the presence of a strong non-nucleophilic base.42. The process according to claim 35 , wherein the aromatisation of the compound of formula (VI) is carried out in the presence of an alcoholate/alcohol couple.43. The process according to claim 42 , wherein the ...

Подробнее
07-11-2013 дата публикации

PROCESS FOR PRODUCING OSELTAMIVIR PHOSPHATE AND INTERMEDIATE COMPOUND

Номер: US20130296600A1
Принадлежит:

Disclosed are a process suited to large scale synthesis with high yield for producing oseltamivir phosphate, in which a preparation of oseltamivir phosphate which is highly safe as a pharmaceutical product can be produced, and an intermediate compound for producing oseltamivir phosphate. In this production process, an intermediate compound represented by general formula (V) is synthesized by employing Michael reaction/Michael reaction/Horner-Wadsworth-Emmons reaction, and oseltamivir phosphate is produced by converting the substituent groups in this intermediate compound. 39-. (canceled) The present invention relates to a process for producing oseltamivir phosphate and an intermediate compound.Influenza is an acute infectious disease caused by an influenza virus, and has been known to allow global pandemic threats to emerge every year. Influenza viruses infect host cells by incorporation of hemagglutinin that is a protein present on the surface of virus particles into host cells via binding to a glycoprotein on the surface of the host cells, followed by proliferation in the host cells, and subsequently the viruses are secreted out of the cells and infect another host cells.When thus proliferated influenza viruses in host cells are secreted out of the cells, glycoproteins present on the cell surface of the host cells form complexes with hemagglutinin present on the surface of the virus particles. For releasing the virus particles from the host cells to infect other host cells, it is necessary to cleave binding between the glycoprotein and hemagglutinin, and the cleavage of this binding is carried out by neuraminidase present on the surface of the virus particles.Oseltamivir phosphate has been known to inhibit the activity of neuraminidase, and has been used as a specific medicine for influenza. Oseltamivir phosphate has been conventionally synthesized by way of semisynthesis using shikimic acid, which is a natural substance, as a starting material (for example, see ...

Подробнее
07-11-2013 дата публикации

Acetamide Stereoisomer

Номер: US20130296607A1
Принадлежит:

The compound of formula (I) 2. A process according to wherein the trialkylsilyl is TBDMS.4. A process according to wherein the trialkylsilyl is TBDMS. This application is a continuation of U.S. patent application Ser. No. 12/196,520, filed Aug. 22, 2008, now allowed. U.S. patent application Ser. No. 12/196,520 claims priority to U.S. Provisional Application No. 60/966,438 filed Aug. 28, 2007. The entire disclosures of each of these applications are hereby incorporated herein by reference.The present invention relates to a novel acetamide stereoisomer, to a process for preparing the acetamide stereoisomer, to a pharmaceutical composition comprising the acetamide stereoisomer and to the use of the acetamide stereoisomer in therapy, in particular in the treatment of bronchoconstriction associated with reversible obstructive airways diseases including but not limited to asthma, cystic fibrosis and chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.Patients suffering from bronchoconstriction associated with reversible obstructive airways diseases are generally treated using a bronchodilator, to relax the bronchial smooth muscle.Bronchodilators in use today generally fall into two classes, the β-selective adrenoceptor agonists, such as albuterol (salbutamol), salmeterol and formoterol, and the muscarinic receptor antagonists, such as ipratropium and tiatropium.β-Selective adrenoceptor agonists may cause adverse effects, and these may in part be due to activation of the β-adrenoceptor. The selectivity of an agonist for the β-adrenoceptor receptor is therefore very important, because it limits the dose that can be given and so affects the magnitude of bronchodilations and the frequency of dosing.A long duration of action is important to patients, not only to minimize the time spent taking the drug, but also to avoid having to take the drug during inconvenient times, for example at work, school or during the night. Some of the more recent β- ...

Подробнее
14-11-2013 дата публикации

CRYSTALLINE FORMS OF THE DI-SODIUM SALT OF N-(5-CHLOROSALICYLOYL)-8-AMINOCAPRYLIC ACID

Номер: US20130303444A1
Принадлежит: Emisphere Technologies, Inc.

The present invention relates to crystalline polymorphic forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, pharmaceutical compositions containing the same, methods of preparing the same, and methods for facilitating the delivery of active agents with the same. 1. Form I of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid.2. A crystalline monohydrate of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid exhibiting an X-ray powder diffraction pattern having at least one peak in degrees 2Θ±0.2° 2Θ selected from 7.5 , 10.4 , 14.2 , 15.0 , 15.5 , 16.1 , 18.4 , 20.8 , 23.6 , 24.1 , 24.5 , 24.8 , 25.4 , 26.6 , 27.2 , 27.5 , 29.6 , and 31.5.3. The crystalline monohydrate of claim 2 , wherein the monohydrate exhibits an X-ray powder diffraction pattern having at least two peaks in degrees 2Θ±0.2° 2θ selected from 7.5 claim 2 , 10.4 claim 2 , 14.2 claim 2 , 15.0 claim 2 , 15.5 claim 2 , 16.1 claim 2 , 18.4 claim 2 , 20.8 claim 2 , 23.6 claim 2 , 24.1 claim 2 , 24.5 claim 2 , 24.8 claim 2 , 25.4 claim 2 , 26.6 claim 2 , 27.2 claim 2 , 27.5 claim 2 , 29.6 claim 2 , and 31.5.4. The crystalline monohydrate of claim 2 , wherein the monohydrate exhibits an X-ray powder diffraction pattern having at least one peak in degrees 2Θ±0.2° 2Θ selected from 15.5 claim 2 , 24.5 claim 2 , and 24.8.5. Form II of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid.6. A crystalline ethanol solvate of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid exhibiting an X-ray powder diffraction pattern having at least one peak in degrees 2Θ±0.2° 2Θ selected from 7.5 claim 2 , 14.1 claim 2 , 16.5 claim 2 , 18.5 claim 2 , 25 claim 2 , and 26.7. The crystalline ethanol solvate of claim 6 , wherein the crystalline ethanol solvate exhibits an X-ray powder diffraction pattern having at least one peak in degrees 2Θ±0.2° 2Θ selected from 16.5 claim 6 , 25 claim 6 , and 26.8. Form III of the disodium salt of N-(5- ...

Подробнее
14-11-2013 дата публикации

POLYMER PRECURSORS OF RADIOLABELED COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME

Номер: US20130303757A1
Принадлежит:

One aspect of the present invention relates to novel compounds that can be used to prepare radiolabeled compounds in an effective manner. A second aspect of the present invention relates to a method of synthesizing radiolabeled compounds. 115-. (canceled)16. A method for preparing a radiolabeled compound , the method comprising: reacting a polymer precursor compound with an oxidant , a radiolabeled compound and optionally a buffer , wherein the compound is selected from the group consisting of:Poly-(4S, 5S)-2-(5-{dibutyl[2-(4-vinylphenyl)ethyl]stannyl}-2,3-dihydrobenzofuran-7-yl)-3, 4-dimethyl-5-phenyl-1, 3-oxazolidine-co-divinylbenzene;Poly-5-{dibutyl[2-(4-vinylphenyl)ethyl]stannyl}-2, 3-dihydrobenzofuran-7-carbaldehyde-co-divinylbenzene;Poly-5-{dibutyl[2-(4-vinylphenyl)ethyl]stannyl}-2, 3-dihydrobenzofuran-7-carboxylic acid-co-divinylbenzene;Poly-(4S, 5S)-2-(4-{dibutyl[2-(3-vinylphenyl)ethyl]stannyl}phenyl)-3, 4-dimethyl-5-pheynyl-1, 3-oxazolidine-co-divinylbenzene; andPoly-(4S, 5S)-2-(4-{dibutyl[2-(4-vinylphenyl)ethyl]stannyl}phenyl)-3, 4-dimethyl-5-phenyl-1, 3-oxazolidine-co-divinylbenzene.17. A method of claim 16 , further comprising a purification of the radiolabeled compound.18. A kit containing a radiolabeling system claim 16 , comprising: a polymer precursor compound and instructions for using said polymer precursor compound claim 16 , wherein said polymer precursor compound comprises the polymer precursor compound of .19. The kit of that further includes a filter or a filtration device.20. The kit of that further includes a chelating agent and optionally an auxiliary molecule.21. A method of synthesizing radiolabeled benzamides on a solid support comprising:a) selecting a solid support comprising at least one compound attached to said solid support which compound comprises a benzoic acid moiety;b) reacting said moiety of said compound attached to said solid support with at least one amine to afford a benzamide bound to a solid support; andc) reacting said ...

Подробнее
14-11-2013 дата публикации

METHOD OF MAKING FATTY ACID N-ACYLALKANOLAMINES

Номер: US20130303795A1
Автор: WANG Tong, Wang Xiaosan

The present invention relates to methods for making a fatty acid N-acylalkanolamine having the formula: 2. The method of claim 1 , wherein the alkanolamine is selected from the group consisting of ethanolamine claim 1 , propanolamine claim 1 , isopropanolamine claim 1 , butanolamine claim 1 , isobutanolamine claim 1 , methylethanolamine claim 1 , butylethanolamine claim 1 , and mixtures thereof.3. The method of claim 1 , wherein the alkanolamine is ethanolamine.4. The method of claim 3 , wherein the fatty acid N-acylalkanolamine is a fatty acid N-acylethanolamine.5. The method of claim 1 , wherein the fatty acid contains from about 4 to about 26 carbon atoms.6. The method of claim 5 , wherein the fatty acid is an unsaturated fatty acid.7. The method of claim 6 , wherein the fatty acid is selected from the group consisting of oleic acid claim 6 , myristoleic acid claim 6 , palmitoleic acid claim 6 , sapienic acid claim 6 , elaidic acid claim 6 , vaccenic acid claim 6 , linoleic acid claim 6 , linoelaidic acid claim 6 , α-linolenic acid claim 6 , arachidonic acid claim 6 , eicosapentaenoic acid claim 6 , erucic acid claim 6 , docosahexaenoic acid claim 6 , and mixtures thereof.8. The method of claim 6 , wherein the fatty acid is oleic acid.9. The method of claim 1 , wherein said reacting is carried out in the presence of at least one solvent.10. The method of claim 9 , wherein the solvent is hexane.11. The method of claim 9 , wherein the solvent is present in a concentration ranging from 30 to 85 wt % of all total reactants.12. The method of claim 9 , wherein the solvent is present in a concentration ranging from 30 to 60 wt % of all total reactants.13. The method of claim 1 , wherein said reacting is carried out with at least one catalyst.14. The method of claim 13 , wherein the catalyst is a lipase.15. The method of claim 14 , wherein the lipase is present in a concentration ranging from 10 to 50 wt % of all total reactants.16. The method of claim 14 , wherein the ...

Подробнее
21-11-2013 дата публикации

METHOD FOR PREPARING 2-AMINOBENZAMIDE DERIVATIVES

Номер: US20130310567A1
Принадлежит: EI DU PONT DE NEMOURS AND COMPANY

A method for preparing a compound of Formula 1 comprising contacting a compound of Formulae 2 and 3 in the presence of a palladium source, a ligand, a base and carbon monoxide 2. The method of wherein Ris C-Calkyl; and Ris Cl or cyano.3. The method of wherein Ris methyl; and Ris chloro.4. The method of wherein Ris methyl; and Ris cyano.5. The method of wherein X is Br.6. The method of wherein Ris H claim 1 , methyl claim 1 , isopropyl or cyclopropylcyclopropyl.7. The of wherein Ris methyl; Ris Cl or cyano; and Ris methyl.8. The method of wherein the base is an organic base comprising a compound of Formula 3; Ris methyl or isopropyl; and the base is in a mole ratio of at least about 2 relative to a compound of Formula 2.9. The method of wherein the palladium source is a palladium(II) species and the ligand is selected from 1 claim 1 ,1′-bis(diphenylphosphino)ferrocene and 1 claim 1 ,4-bis(diphenylphosphino)butane.10. The method of wherein the palladium source is palladium(II) acetate and the ligand is 1 claim 9 ,4-bis(diphenylphosphino)butane.11. The method of wherein the contacting is performed in a suitable solvent comprising ethylene glycol and N claim 1 ,N-dimethylethanolamine.13. The method of wherein the palladium source is a palladium(II) species and the ligand is 1 claim 12 ,1′-bis(diphenylphosphino)ferrocene; and the contacting is performed in a suitable solvent comprising ethylene glycol and N claim 12 ,N-dimethylethanolamine.15. The method of wherein Ris CH; Ris Cl or cyano; Ris CH claim 14 , Ris Br; Ris Cl; Ris H; and Z is N. This invention relates to a method for preparing 2-aminobenzamides and derivatives thereof.Preparation of certain 2-aminobenzamides and their utility as intermediates for preparing insecticidal anthranilic diamides is disclosed in PCT Patent Publication WO 06/062978. However, the need continues for new or improved methods suitable for rapidly and economically providing 2-aminobenzamides and their derivatives.This invention is ...

Подробнее
21-11-2013 дата публикации

CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN

Номер: US20130310577A1
Принадлежит: DSM IP ASSETS B.V.

Described is a method for the preparation of renin inhibitors such as aliskiren, and intermediates useful therein. The method introduces a nitrogen-containing intermediate such as a lactone of formula (8). 3. A compound according to or , wherein Ris 2-propyl.5. A method according to claim 4 , wherein the reaction is conducted in the presence of a chiral catalyst.6. A method according to claim 5 , wherein the chiral catalyst is an enzyme.7. A method according to claim 6 , wherein the enzyme hydroxynitrile lyase. This application is a divisional of commonly owned U.S. application Ser. No. 12/810,220, filed Sep. 22, 2010 (now U.S. Pat. No. ______), which is the national phase application under 35 USC §371 of PCT/EP2008/009050, Dec. 19, 2008, which designated the US and claims benefit of EP Patent Application No. 07025093.1, filed Dec. 24, 2007, the entire contents of each of which are hereby incorporated by reference.The invention pertains to a convergent synthesis route for the preparation of certain 2(S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amide derivatives, or pharmaceutically acceptable salts thereof, such as the compound aliskiren. The invention particularly relates to a synthetic route that will introduce the nitrogen of the above mentioned compounds ultimately required for the amino-group at C-5, at a relative early stage of the synthesis. The invention further relates to novel intermediates useful in the manufacture of the above mentioned compounds. Particularly, the 2(S),4(S),5(S),7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amide derivatives to which the methods of the present invention applies are any of those having renin inhibitory activity and, therefore, pharmaceutical utility, e.g., those disclosed in U.S. Pat. No. 5,559,111, WO 2006/061427, or WO 2006/095020.The 2(S),4(S),5(S);7(S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amide derivatives, or pharmaceutically acceptable salts thereof to which the invention pertains, ...

Подробнее
28-11-2013 дата публикации

Process for the preparation of lacosamide

Номер: US20130317109A1
Принадлежит: CAMBREX KARLSKOGA AB

There is provided a process for the preparation of Lacosamide (which is a useful medicament) of formula I, which comprises an enantioselective enzymatic acylation.

Подробнее
28-11-2013 дата публикации

PROCESS FOR PRODUCTION OF AROMATIC AMIDE CARBOXYLIC ACID DERIVATIVE

Номер: US20130317247A1
Принадлежит: MITSUI CHEMICALS AGRO, INC.

The invention provides a method for producing an aromatic amide carboxylic acid derivative represented by the following Formula (2), including a step of reacting an aromatic amide halide derivative represented by the following Formula (1) with carbon monoxide. In the following Formulae (1) and (2), Rrepresents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; Xrepresents a fluorine atom or a cyano group; Xrepresents a halogen atom; and n represents an integer of from 0 to 3. 5. The aromatic amide halide derivative according to claim 4 , wherein claim 4 , in Formula (1) claim 4 , Rrepresents a methyl group claim 4 , Xrepresents a fluorine atom claim 4 , Xrepresents a chlorine atom claim 4 , and n represents 0 or 1. The invention relates to a method for producing an aromatic amide carboxylic acid derivative.Methods for producing aromatic carboxylic acid derivatives are known in which carbon monoxide is inserted into a certain kind of aromatic halide derivative in the presence of a base and water, using a palladium compound as a catalyst (see, for example, Japanese Patent Application Laid-Open (JP-A) Nos. 8-104661, 2003-48859, and 2005-220107).Furthermore, a method for producing an aromatic amide carboxylic acid derivative having an amide bond and a halogen atom, etc., in the molecule thereof is known (see, for example, International Patent Publication No. WO 2010/18857).The inventors have studied industrial methods for producing aromatic amide carboxylic acid derivatives using the methods described in the above known art. However, the methods require multi-step reactions and are therefore insufficient as industrial production methods.The invention provides a method that allows for the production of an aromatic amide carboxylic acid derivative having a halogen atom, etc., through fewer process steps, and a useful intermediate for use in the production method.As a result of the intensive studies to develop a method that allows for the production of an ...

Подробнее
05-12-2013 дата публикации

Processes for producing hexamethylenediamine (hmd), adiponitrile (adn), adipamide (adm) and derivatives thereof

Номер: US20130324694A1
Принадлежит: Bioamber SAS

Processes for producing nitrogen containing compounds include producing hexamethylenediamine (HMD), adiponitrile (ADN), adipamide (ADM) and derivatives thereof from adipic acid (AA) obtained from fermentation broths containing diammonium adipate (DAA) or monoammonium adipate (MAA).

Подробнее
12-12-2013 дата публикации

Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates

Номер: US20130331610A1
Принадлежит: Ferrer Internacional, S.A.

The invention provides novel halogenated pyrazolo[1,5-a]pyrimidines of formula (I) wherein R, R, X and Y have different meanings, and pharmaceutically acceptable salts thereof. Compounds of formula (I) are useful for treating or preventing anxiety, epilepsy and sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation. The invention also provides synthetic procedures for preparing said compounds and certain intermediates, as well as intermediates themselves. 2. The process of wherein the hydride compound is sodium hydride and Z is iodine.6. An intermediate enaminone compound which is selected from the group consisting of:N-[5-(3-dimethylamino-acryloyl)-2-fluoro-phenyl]-N-methyl-acetamide;N-[2-chloro-5-(3-dimethylamino-acryloyl)-phenyl]-N-methyl-acetamide;N-[5-(3-dimethylamino-acryloyl)-2-fluoro-phenyl]-N-methyl-methanesulfonamide;N-[2-chloro-5-(3-dimethylamino-acryloyl)-phenyl]-N-methyl-methanesulfonamide; andN-[5-(3-dimethylamino-acryloyl)-2-fluoro-phenyl]-N-prop-2-ynyl-methanesulfonamide. This application is a Divisional Application of U.S. patent application Ser. No. 11/922,602, filed Apr. 30, 2009, which is the U.S. National Phase of PCT/EP2006/063243, filed Jun. 15, 2006, which claims benefit of Provisional Application No. 60/692,866 filed on Jun. 21, 2005. This application also claims priority under 35 U.S.C. §119(a) to European Patent Application No. 05105478.1, filed in Europe on Jun. 21, 2005, the entire contents of which are hereby incorporated by reference.This invention is directed to agents with affinity for GABAreceptor, specifically to halogenated pyrazolo[1,5-a]pyrimidines, and more specifically to [7-(3-amino-4-halophenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-thiophen-2-yl-methanone acyl and sulfonyl compounds.GABAreceptor (γ-aminobutyric acid) is a pentameric protein which forms a membrane ion channel. GABAreceptor is implicated in the regulation of sedation, anxiety, muscle tone, epileptogenic ...

Подробнее
02-01-2014 дата публикации

NOVEL COMPOUNDS, METHOD FOR PREPARATION THEREOF AND USE THEREOF FOR PREPARING POLYMERS USEFUL FOR INCREASING HEAT RESISTANCE OF POLYMERIC COMPOSITIONS

Номер: US20140005351A1
Принадлежит:

The invention relates to a compound of the following formula (I): to its method for making it and to its uses for preparing a polymer useful for increasing the heat resistance of polymeric compositions. 2. The compound according to claim 1 , wherein p and n are identical and independently represent an integer from 3 to 12 and m represents (n−2).3. The compound according to claim 1 , wherein n claim 1 , m and p are even integers.4. The compound according to claim 1 , wherein m represents 2 or 3.5. The compound according to claim 4 , wherein n and p represent 4 and m represents 2 or n and p represent 5 and m represents 3.7. A method for preparing a (PEA) polymer comprising a step consisting of heating to a temperature greater than or equal to the melting temperature of the compound of formula (I) and under reduced pressure claim 1 , a compound of formula (I) according to claim 1 , in the presence of a catalyst claim 1 , in order to polymerize said compound of formula (I).9. The method for preparing a (PEA) polymer according to claim 1 , wherein the compound of formula (I) is the compound according to .10. A (PEA) polymer obtainable by a method comprising a step consisting of heating a compound of formula (I) according to to a temperature greater than or equal to the melting temperature of said compound of formula (I) and under reduced pressure claim 5 , in the presence of a catalyst claim 5 , in order to polymerize said compound of formula (I).11. A method for improving the heat resistance of a composition claim 10 , comprising the step of adding to said composition a (PEA) polymer according to .12. A composition comprising:{'claim-ref': {'@idref': 'CLM-00010', 'claim 10'}, 'a (PEA) polymer according to ,'}optionally at least one other polymer (P), andoptionally natural fibers.13. A plastic article comprising a composition according to .14. The method for preparing a (PEA) polymer according to claim 8 , wherein the compound of formula (I) is brought into contact with ...

Подробнее